UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the quarterly period ended ~~September 30, 2022~~March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 0-16211

DENTSPLY SIRONA Inc.

(Exact name of registrant as specified in its charter)


Delaware						39-1434669
(State or other jurisdiction of						(I.R.S. Employer
incorporation or organization)						Identification No.)

13320 Ballantyne Corporate Place, Charlotte, North Carolina						28277-3607
(Address of principal executive offices)						(Zip Code)

(844) 848-0137

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer x			Accelerated filer ☐
Non-accelerated filer ☐			Smaller reporting company ☐
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: At ~~November 3, 2022,~~April 25, 2023, DENTSPLY SIRONA Inc. had ~~214,911,886~~212,477,811 shares of common stock outstanding.

~~EXPLANATORY NOTE~~

As described in additional detail in the Explanatory Notes to its Amendment No. 1 to its Annual Report on Form 10-K/A for the fiscal year ended December 31, 2021 (the "2021 Form 10-K/A") and Amendment No. 1 to its Quarterly Report on Form 10-Q/A for the quarter ended September 30, 2021 (the "Form 10-Q/A"), DENTSPLY SIRONA Inc. (the "Company"), restated its audited consolidated financial statements for the fiscal year ended December 31, 2021 and the unaudited consolidated financial statements for the quarter ended September 30, 2021.

The impact of the restatement on the Company's consolidated financial statements included herein is further described in Note 1, Significant Accounting Policies and Restatement. The comparative financial information for the three and nine months ended September 30, 2021 provided herein should be read in conjunction with the applicable financial statements and accompanying notes of the Company, as provided in the 2021 Form 10-K/A and the Form 10-Q/A.

DENTSPLY SIRONA Inc.

TABLE OF CONTENTS

General

Unless otherwise stated herein or the context otherwise indicates, reference throughout this Form 10-Q to “Dentsply Sirona,” or the “Company,” “we,” “us” or “our” refers to financial information and transactions of DENTSPLY SIRONA Inc., together with its subsidiaries on a consolidated basis.

Forward-Looking Statements and Associated Risks

All statements in this Form 10-Q that do not directly and exclusively relate to historical facts constitute “forward-looking statements” and include statements related to our ability to successfully remediate the material weaknesses in our internal control over financial reporting disclosed in this Form 10-Q in the manner currently anticipated. These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part ~~II, Item 1A “Risk Factors” of this Form 10-Q and in Part~~ I, Item 1A, “Risk Factors” of ~~Amendment No. 1 to~~ the Company's Annual Report on Form ~~10-K/A~~10-K for the fiscal year ended December 31, ~~2021 filed on~~ 2022 (the "2022 Form 10-K"),~~November 7, 2022,~~ and other factors which may be described in the Company’s other filings with the Securities and Exchange Commission (the “SEC”). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Form 10-Q or to reflect the occurrence of unanticipated events.

Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company’s SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(in millions, except per share amounts)

(unaudited)


		Three Months Ended September 30,				Nine Months Ended September 30,					Three Months Ended March 31,
		2022		2021		2022		2021			2023		2022

Net sales	Net sales	$	947	$	1,040	$	2,939	$	3,128	Net sales	$	978	$	969
Cost of products sold	Cost of products sold	439		471		1,329		1,385		Cost of products sold	459		448

Gross profit	Gross profit	508		569		1,610		1,743		Gross profit	519		521
Selling, general, and administrative expenses	Selling, general, and administrative expenses	401		395		1,187		1,174		Selling, general, and administrative expenses	416		376
Research and development expenses	Research and development expenses	41		39		131		122		Research and development expenses	46		45
Goodwill impairment		1,187		—		1,187		—
Intangible asset impairment and other costs		97		3		107		11

Restructuring and other costs										Restructuring and other costs	59		3

Operating (loss) income	Operating (loss) income	(1,218)		132		(1,002)		436		Operating (loss) income	(2)		97

Other income and expenses:	Other income and expenses:									Other income and expenses:
Interest expense, net	Interest expense, net	14		14		41		43		Interest expense, net	19		12

Other expense (income), net	Other expense (income), net	9		5		20		4		Other expense (income), net	7		(2)

(Loss) income before income taxes	(Loss) income before income taxes	(1,241)		113		(1,063)		389		(Loss) income before income taxes	(28)		87
(Benefit) provision for income taxes	(Benefit) provision for income taxes	(164)		29		(128)		97		(Benefit) provision for income taxes	(5)		18

Net (loss) income	Net (loss) income	(1,077)		84		(935)		292		Net (loss) income	(23)		69

Less: Net income attributable to noncontrolling interest		—		—		—		—
Less: Net loss attributable to noncontrolling interest										Less: Net loss attributable to noncontrolling interest	(4)		—

Net (loss) income attributable to Dentsply Sirona	Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292	Net (loss) income attributable to Dentsply Sirona	$	(19)	$	69

Net (loss) income per common share attributable to Dentsply Sirona:	Net (loss) income per common share attributable to Dentsply Sirona:									Net (loss) income per common share attributable to Dentsply Sirona:
Basic	Basic	$	(5.01)	$	0.39	$	(4.34)	$	1.34	Basic	$	(0.09)	$	0.32
Diluted	Diluted	$	(5.01)	$	0.38	$	(4.34)	$	1.32	Diluted	$	(0.09)	$	0.32

Weighted average common shares outstanding:	Weighted average common shares outstanding:									Weighted average common shares outstanding:
Basic	Basic	214.9		218.6		215.6		218.6		Basic	214.5		217.0
Diluted	Diluted	214.9		220.5		215.6		220.7		Diluted	214.5		217.8

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(in millions)

(unaudited)


	Three Months Ended March 31,
	2023		2022


Net (loss) income	$	(23)	$	69

Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	15		(48)
Net (loss) gain on derivative financial instruments	(1)		10

Pension liability gain	—		1
Total other comprehensive income (loss), net of tax	14		(37)

Total comprehensive (loss) income	(9)		32

Less: Comprehensive loss attributable to noncontrolling interests	(4)		—

Total comprehensive (loss) income attributable to Dentsply Sirona	$	(5)	$	32

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED ~~STATEMENTS OF COMPREHENSIVE INCOME (LOSS)~~BALANCE SHEETS

(in ~~millions)~~

~~(unaudited)~~

Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
Net (loss) income $ (1,077) $ 84 $ (935) $ 292
Other comprehensive loss, net of tax:
Foreign currency translation loss (148) (68) (310) (130)
Net gain on derivative financial instruments 22 10 54 19
Pension liability gain 1 2 4 8
Total other comprehensive loss, net of tax (125) (56) (252) (103)
Total comprehensive (loss) income (1,202) 28 (1,187) 189
Less: Comprehensive income attributable to noncontrolling interests — — — —
Total comprehensive (loss) income attributable to Dentsply Sirona $ (1,202) $ 28 $ (1,187) $ 189
millions, except per share amounts)

(unaudited)


	March 31, 2023		December 31, 2022

Assets
Current Assets:
Cash and cash equivalents	$	318	$	365
Accounts and notes receivables-trade, net	652		632
Inventories, net	659		627
Prepaid expenses and other current assets	314		269
Total Current Assets	1,943		1,893

Property, plant, and equipment, net	770		761
Operating lease right-of-use assets, net	191		200
Identifiable intangible assets, net	1,862		1,903
Goodwill	2,701		2,688
Other noncurrent assets	206		198
Total Assets	$	7,673	$	7,643

Liabilities and Equity
Current Liabilities:
Accounts payable	$	267	$	279
Accrued liabilities	748		727
Income taxes payable	43		46
Notes payable and current portion of long-term debt	316		118
Total Current Liabilities	1,374		1,170

Long-term debt	1,842		1,826
Operating lease liabilities	144		149
Deferred income taxes	271		287
Other noncurrent liabilities	404		399
Total Liabilities	4,035		3,831

Commitments and contingencies (Note 14)

Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	—		—
Common stock, $0.01 par value;	3		3
400.0 million shares authorized, and 264.5 million shares issued at March 31, 2023 and December 31, 2022
212.5 million and 215.3 million shares outstanding at March 31, 2023 and December 31, 2022
Capital in excess of par value	6,604		6,629
Retained earnings	407		456
Accumulated other comprehensive loss	(614)		(628)
Treasury stock, at cost, 52.0 million and 49.3 million shares at March 31, 2023 and December 31, 2022, respectively	(2,759)		(2,649)
Total Dentsply Sirona Equity	3,641		3,811

Noncontrolling interests	(3)		1
Total Equity	3,638		3,812
Total Liabilities and Equity	$	7,673	$	7,643

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

~~DENTSPLY SIRONA INC. AND SUBSIDIARIES~~

~~CONSOLIDATED BALANCE SHEETS~~

~~(in millions, except per share amounts)~~

~~(unaudited)~~
September 30, 2022 December 31, 2021
Assets
Current Assets:
Cash and cash equivalents $ 418 $ 339
Accounts and notes receivables-trade, net 645 750
Inventories, net 592 515
Prepaid expenses and other current assets 284 248
Total Current Assets 1,939 1,852
Property, plant, and equipment, net 714 773
Operating lease right-of-use assets, net 201 198
Identifiable intangible assets, net 1,875 2,319
Goodwill 2,584 3,976
Other noncurrent assets 209 121
Total Assets $ 7,522 $ 9,239
Liabilities and Equity
Current Liabilities:
Accounts payable $ 271 $ 262
Accrued liabilities 711 760
Income taxes payable 68 57
Notes payable and current portion of long-term debt 246 182
Total Current Liabilities 1,296 1,261
Long-term debt 1,737 1,913
Operating lease liabilities 154 149
Deferred income taxes 246 391
Other noncurrent liabilities 475 528
Total Liabilities 3,908 4,242
Commitments and contingencies (Note 15)
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued — —
Common stock, $0.01 par value; 3 3
400.0 million shares authorized, and 264.5 million shares issued at September 30, 2022 and December 31, 2021
214.9 million and 217.4 million shares outstanding at September 30, 2022 and December 31, 2021
Capital in excess of par value 6,619 6,606
Retained earnings 498 1,514
Accumulated other comprehensive loss (844) (592)
Treasury stock, at cost, 49.6 million and 47.1 million shares at September 30, 2022 and December 31, 2021, respectively (2,663) (2,535)
Total Dentsply Sirona Equity 3,613 4,996
Noncontrolling interests 1 1
Total Equity 3,614 4,997
Total Liabilities and Equity $ 7,522 $ 9,239

~~See accompanying Notes to Unaudited Interim Consolidated Financial Statements.~~

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(in millions, except per share amounts)

(unaudited)

Common
Stock Capital in
Excess of
Par Value Retained
Earnings Accumulated
Other
Comprehensive
Loss Treasury
Stock Total Dentsply Sirona
Equity Noncontrolling
Interests Total
Equity
Balance at December 31, 2021 $ 3 $ 6,606 $ 1,514 $ (592) $ (2,535) $ 4,996 $ 1 $ 4,997
Net income — — 69 — — 69 — 69
Other comprehensive loss — — — (37) — (37) — (37)
Exercise of stock options — 1 — — 4 5 — 5
Stock based compensation expense — 11 — — — 11 — 11
Funding of employee stock purchase plan — 1 — — 1 2 — 2
Accelerated share repurchase — (30) — — (120) (150) — (150)
Restricted stock unit distributions — (16) — — 10 (6) — (6)
Cash dividends declared ($0.125 per share) — — (27) — — (27) — (27)
Balance at March 31, 2022 $ 3 $ 6,573 $ 1,556 $ (629) $ (2,640) $ 4,863 $ 1 $ 4,864
Net income — — 73 — — 73 — 73
Other comprehensive loss — — — (90) — (90) — (90)
Exercise of stock options — — — — 2 2 — 2
Stock based compensation expense — 16 — — — 16 — 16
Funding of employee stock purchase plan — — — — 1 1 — 1
Accelerated share repurchase — 30 — — (30) — — —
Restricted stock unit distributions — (3) — — 1 (2) — (2)
Restricted stock unit dividends — 1 (1) — — — — —
Cash dividends declared ($0.125 per share) — — (26) — — (26) — (26)
Balance at June 30, 2022 $ 3 $ 6,617 $ 1,602 $ (719) $ (2,666) $ 4,837 $ 1 $ 4,838
Net loss — — (1,077) — — (1,077) — (1,077)
Other comprehensive loss — — — (125) — (125) — (125)
Stock based compensation expense — 3 — — — 3 — 3
Funding of employee stock purchase plan — — — — 3 3 — 3
Restricted stock unit distributions — (1) — — — (1) — (1)
Cash dividends ($0.125 per share) — — (27) — — (27) — (27)
Balance at September 30, 2022 $ 3 $ 6,619 $ 498 $ (844) $ (2,663) $ 3,613 $ 1 $ 3,614


	Common Stock		Capital in Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total Dentsply Sirona Equity		Noncontrolling Interests		Total Equity

Balance at December 31, 2022	$	3	$	6,629	$	456	$	(628)	$	(2,649)	$	3,811	$	1	$	3,812
Net loss	—		—		(19)		—		—		(19)		(4)		(23)
Other comprehensive income	—		—		—		14		—		14		—		14


Stock based compensation expense	—		17		—		—		—		17		—		17
Funding of employee stock purchase plan	—		—		—		—		3		3		—		3

Accelerated share repurchase	—		(30)		—		—		(121)		(151)		—		(151)

Restricted stock unit distributions	—		(12)		—		—		8		(4)		—		(4)

Cash dividends declared ($0.14 per share)	—		—		(30)		—		—		(30)		—		(30)
Balance at March 31, 2023	$	3	$	6,604	$	407	$	(614)	$	(2,759)	$	3,641	$	(3)	$	3,638


		Common Stock		Capital in Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total Dentsply Sirona Equity		Noncontrolling Interests		Total Equity			Common Stock		Capital in Excess of Par Value		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total Dentsply Sirona Equity		Noncontrolling Interests		Total Equity

Balance at December 31, 2020		$	3	$	6,604	$	1,198	$	(464)	$	(2,409)	$	4,932	$	3	$	4,935
Balance at December 31, 2021																		Balance at December 31, 2021	$	3	$	6,606	$	1,514	$	(592)	$	(2,535)	$	4,996	$	1	$	4,997
Net income	Net income	—		—		112		—		—		112		—		112		Net income	—		—		69		—		—		69		—		69
Other comprehensive loss	Other comprehensive loss	—		—		—		(90)		—		(90)		—		(90)		Other comprehensive loss	—		—		—		(37)		—		(37)		—		(37)

Exercise of stock options	Exercise of stock options	—		11		—		—		22		33		—		33		Exercise of stock options	—		1		—		—		4		5		—		5
Stock based compensation expense	Stock based compensation expense	—		13		—		—		—		13		—		13		Stock based compensation expense	—		11		—		—		—		11		—		11
Funding of employee stock purchase plan	Funding of employee stock purchase plan	—		1		—		—		2		3		—		3		Funding of employee stock purchase plan	—		1		—		—		1		2		—		2
Treasury shares purchased		—		—		—		—		(90)		(90)		—		(90)
Accelerated share repurchase																		Accelerated share repurchase	—		(30)		—		—		(120)		(150)		—		(150)
Restricted stock unit distributions	Restricted stock unit distributions	—		(11)		—		—		7		(4)		—		(4)		Restricted stock unit distributions	—		(16)		—		—		10		(6)		—		(6)

Cash dividends declared ($0.10 per share)		—		—		(22)		—		—		(22)		—		(22)
Balance at March 31, 2021		$	3	$	6,618	$	1,288	$	(554)	$	(2,468)	$	4,887	$	3	$	4,890
Net income		—		—		96		—		—		96		—		96
Other comprehensive income		—		—		—		43		—		43		—		43

Exercise of stock options		—		3		—		—		9		12		—		12

Stock based compensation expense		—		19		—		—		—		19		—		19
Cash dividends declared ($0.125 per share)																		Cash dividends declared ($0.125 per share)	—		—		(27)		—		—		(27)		—		(27)
Balance at March 31, 2022																		Balance at March 31, 2022	$	3	$	6,573	$	1,556	$	(629)	$	(2,640)	$	4,863	$	1	$	4,864

Restricted stock unit distributions		—		(2)		—		—		1		(1)		—		(1)

Cash dividends declared ($0.11 per share)		—		—		(25)		—		—		(25)		—		(25)
Balance at June 30, 2021		$	3	$	6,638	$	1,359	$	(511)	$	(2,458)	$	5,031	$	3	$	5,034
Net income		—		—		84		—		—		84		—		84
Other comprehensive loss		—		—		—		(56)		—		(56)		—		(56)
Exercise of stock options		—		—		—		—		1		1		—		1
Stock based compensation expense		—		23		—		—		—		23		—		23
Funding of employee stock purchase plan		—		1		—		—		2		3		—		3

Restricted stock unit distributions		—		(4)		—		—		1		(3)		—		(3)
Restricted stock unit dividends		—		1		(1)		—		—		—		—		—
Cash dividends ($0.11 per share)		—		—		(23)		—		—		(23)		—		(23)
Balance at September 30, 2021		$	3	$	6,659	$	1,419	$	(567)	$	(2,454)	$	5,060	$	3	$	5,063

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

DENTSPLY SIRONA INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in millions)

(unaudited)


		Nine Months Ended September 30,					Three Months Ended March 31,
		2022		2021			2023		2022

Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net (loss) income	Net (loss) income	$	(935)	$	292	Net (loss) income	$	(23)	$	69

Adjustments to reconcile net income to net cash provided by operating activities:
Adjustments to reconcile net (loss)/income to net cash provided by operating activities:						Adjustments to reconcile net (loss)/income to net cash provided by operating activities:
Depreciation	Depreciation	90		94		Depreciation	31		29
Amortization of intangible assets	Amortization of intangible assets	159		167		Amortization of intangible assets	53		55

Fixed asset impairment						Fixed asset impairment	4		—

Goodwill impairment		1,187		—
Indefinite-lived intangible asset impairment		94		—

Deferred income taxes	Deferred income taxes	(220)		(11)		Deferred income taxes	(21)		(14)
Stock based compensation expense	Stock based compensation expense	47		54		Stock based compensation expense	17		11

Restructuring and other costs						Restructuring and other costs	48		(2)

Other non-cash expense	Other non-cash expense	38		13		Other non-cash expense	9		2

Gain on sale of non-strategic businesses and product lines		—		(14)

Changes in operating assets and liabilities, net of acquisitions:	Changes in operating assets and liabilities, net of acquisitions:					Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	Accounts and notes receivable-trade, net	43		(89)		Accounts and notes receivable-trade, net	(15)		34
Inventories, net	Inventories, net	(140)		(88)		Inventories, net	(30)		(41)
Prepaid expenses and other current assets, net	Prepaid expenses and other current assets, net	(46)		(24)		Prepaid expenses and other current assets, net	(17)		(17)
Other noncurrent assets	Other noncurrent assets	(13)		(12)		Other noncurrent assets	(1)		3
Accounts payable	Accounts payable	40		(45)		Accounts payable	(14)		19
Accrued liabilities	Accrued liabilities	(2)		70		Accrued liabilities	(31)		(51)
Income taxes	Income taxes	41		6		Income taxes	(37)		3
Other noncurrent liabilities	Other noncurrent liabilities	(8)		22		Other noncurrent liabilities	6		(7)
Net cash provided by operating activities		375		435
Net cash (used in) provided by operating activities						Net cash (used in) provided by operating activities	(21)		93

Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Capital expenditures	Capital expenditures	(117)		(101)		Capital expenditures	(39)		(44)

Cash paid for acquisitions of businesses and equity investments, net of cash acquired		—		(248)
Cash received on sale of non-strategic businesses or product lines		—		27

Cash received on derivative contracts	Cash received on derivative contracts	10		1		Cash received on derivative contracts	2		1

Other investing activities		(2)		2

Net cash used in investing activities	Net cash used in investing activities	(109)		(319)		Net cash used in investing activities	(37)		(43)

Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:
Cash paid for accelerated share repurchase		(150)		—
Cash paid for treasury stock						Cash paid for treasury stock	(150)		(150)
Proceeds on short-term borrowings	Proceeds on short-term borrowings	64		147		Proceeds on short-term borrowings	198		163
Cash paid for treasury stock		—		(90)
Cash dividends paid	Cash dividends paid	(78)		(68)		Cash dividends paid	(27)		(24)

Proceeds from long-term borrowings, net of deferred financing costs	Proceeds from long-term borrowings, net of deferred financing costs	7		15		Proceeds from long-term borrowings, net of deferred financing costs	—		5
Repayments on long-term borrowings	Repayments on long-term borrowings	(2)		(297)		Repayments on long-term borrowings	—		(2)

Proceeds from exercised stock options	Proceeds from exercised stock options	6		47		Proceeds from exercised stock options	—		5

Other financing activities, net	Other financing activities, net	(15)		(11)		Other financing activities, net	(4)		(7)
Net cash used in financing activities		(168)		(257)
Net cash provided by (used in) financing activities						Net cash provided by (used in) financing activities	17		(10)
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(19)		(16)		Effect of exchange rate changes on cash and cash equivalents	(6)		(5)
Net increase (decrease) in cash and cash equivalents		79		(157)
Net (decrease) increase in cash and cash equivalents						Net (decrease) increase in cash and cash equivalents	(47)		35
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	339		438		Cash and cash equivalents at beginning of period	365		339
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	418	$	281	Cash and cash equivalents at end of period	$	318	$	374

See accompanying Notes to Unaudited Interim Consolidated Financial Statements.

108

DENTSPLY SIRONA Inc. and Subsidiaries

NOTES TO UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – SIGNIFICANT ACCOUNTING POLICIES ~~AND RESTATEMENT~~

Basis of Presentation

The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form ~~10-K/A~~10-K for the year ended December 31, ~~2021, as amended and filed~~ ~~on November 7, 2022.~~

~~Recently Concluded Investigation~~

As previously disclosed, the Audit and Finance Committee of the Company's Board of Directors (the "Audit and Finance Committee"), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. The investigation was conducted in two components, one pertaining to allegations regarding the Company’s use of incentives to sell products to certain distributors in North America in the third and fourth quarters of 2021 (the "North American Investigation") and another to analyze the increase in returns of products in China during the fourth quarter of 2021 identified by the Company (the "China Investigation"). In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee found that certain former members of senior management, including the Company's former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company's Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. The North America Investigation found that certain former members of senior management, including the former Chief Executive Officer and the former Chief Financial Officer created a culture where employees did not feel comfortable raising concerns without fear of retaliation. In addition, the North America Investigation substantiated certain allegations regarding inappropriate tone at the top by the former Chief Executive Officer and the former Chief Financial Officer. Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company's local commercial team in China, as well as the head of the Company's Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company's local accounting team, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company's local commercial team in China, as well as the former Chief Financial Officer and the head of the Company's Asia-Pacific commercial organization, violated the Company's Code of Ethics and Business Conduct.

~~On October 29, 2022, the Audit and Finance Committee determined that its investigation was complete.~~

~~Prior Restatement and Other Corrections of Previously Issued Consolidated Financial Statements~~

The interim consolidated financial statements include previously-made corrections to the three-month and nine-month periods ended September 30, 2021 which were presented in Note 1 to the interim consolidated financial statements and notes thereto for these same periods in the Company's Form 10-Q/A filed on November 7, 2022. This restatement corrected for errors related to certain customer incentive programs as well as the accounting and assumptions in the determination of estimates related to the Company’s sales returns provisions, warranty reserve provisions and variable consideration. In addition, a failure to appropriately account for certain product returns and/or exchanges identified as part of the China investigation referred to above resulted in an overstatement of Net sales in the third quarter of 2021 of approximately $4 million which should have been recorded in the fourth quarter of 2021, and was also reflected in the restated interim financial statements for the three and nine month periods ended September 30, 2021. ~~In conjunction with making these corrections, the Company has also made certain other restatements and revisions for previously identified errors.~~ The restatement from these collective errors resulted in a decrease to Net sales by $29 million, a decrease to Gross profit by $22 million, a decrease to Operating income of $27 million and a decrease to Diluted EPS by $0.09 per share from amounts previously reported for the three-month period ended September 30, 2021. The restatement resulted in a decrease to Net sales by $35 million, a decrease to Gross profit by $25 million, a decrease to Operating income of $32 million and a decrease to Diluted EPS by $0.13 per share from amounts previously reported for the nine-month period ended September 30, 2021.

In order to correct these errors, management previously restated the Company's consolidated financial statements as of and for the three and nine months ended September 30, 2021 which are presented as the comparative periods in the accompanying consolidated financial statements, and also restated as necessary the comparative periods presented in the related notes included herein to correct these accounting errors. For details of these restatements on the previously issued financial statements for these periods, refer to Note 1 of the interim consolidated financial statements in the Company's Form 10-Q/A filed on November 7, 2022. The Company also restated its consolidated financial statements for the fiscal year ended December 31, 2021 in its Form 10-K/A filed on November 7, 2022.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates.

Specifically, for the three months ended September 30, 2022, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company's financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, although demand for the Company’s products has largely recovered from the impact of rigorous preventive measures implemented at the outset of the pandemic, it continues to be affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. Also, impacts from the pandemic continue to be experienced in the form of shortages for specific materials such as electronic components, higher related transportation costs, and labor shortages. Throughout 2022, the Company has continued to experience supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. In the third quarter the Company has been further impacted by deteriorating macroeconomic conditions more generally, including rising global interest rates and inflationary pressures which have raised the price of inputs, impacted the discretionary spending behavior of our customers, and introduced new competitive challenges. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue or whether future variants of the virus may have an adverse impact in affected markets.Recently Adopted Accounting Pronouncements

12In October 2021, the Financial Accounting Standards Board ("FASB") issued ASU No. 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new standard requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. The amendments in this update were effective for the fiscal years and interim periods ending after December 31, 2022. The Company adopted this accounting standard on January 1, 2023. The adoption of this standard did not materially impact the Company's consolidated financial statements or related disclosures.

Accounting Pronouncements Not Yet Adopted

In March 2020, the ~~Financial Accounting Standards Board ("FASB")~~FASB issued ASU No. 2020-04 ~~"Reference~~“Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial ~~Reporting"~~Reporting”, which was subsequently amended by ASU No. 2021-01 ~~"Reference~~“Reference Rate Reform (Topic 848): ~~Scope"~~Scope” in January ~~2021.~~2021 and by ASU No. 2022-06 “Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848” in December 2022. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate ("LIBOR") or another rate expected to be discontinued due to the reference rate reform. This standard was effective upon issuance. The ~~amendments in~~adoption of this standard ~~were effective upon issuance and generally can be applied to contract modifications made or evaluated through December 31, 2022. The Company does~~did not ~~expect this standard to have a material~~materially impact ~~on its~~the Company's consolidated financial statements ~~and related disclosures.~~

In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805)", which requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements andor related disclosures.

Seasonality

Our business is subject to quarterly fluctuations in demand due to price changes, marketing and promotional programs, management of inventory levels by distributors and other customers, and implementation of strategic initiatives which may impact sales levels in any given period. Demand can also fluctuate based on the timing of dental tradeshows where promotions are offered, new product introductions, and variability in dental patient traffic, which can be exacerbated by seasonal ~~fluctuations. Our~~or severe weather patterns, other demographic disruptions such as the recent COVID-19 pandemic, or macroeconomic conditions. Some dental practices in certain countries may also delay purchasing equipment and restocking consumables until year-end due to tax or other financial or budget planning which can impact the timing of our consolidated net sales, net income and ~~profits~~cash flows. Sales for the industry and the Company are ~~typically~~generally strongest in the ~~highest during the third~~second and fourth quarters and weaker in the first and third quarters, due to ~~DS World, our annual dental conference, which historically has occurred near~~ the ~~end~~effects of ~~September. As a result, a disproportionate amount~~the items noted above and due to the impact of ~~operating cash flows is generated in the fourth quarter of our fiscal year. Despite a significant portion of these sales occurring in the third~~holidays and ~~fourth quarter, there are operating expenses, principally advertising and promotional expenses,~~vacations, particularly throughout ~~the year.~~Europe. Because of the seasonal nature of ~~the Company's~~our business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year.

NOTE 2 - REVENUE

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


		Three Months Ended				Nine Months Ended					Three Months Ended
(in millions)	(in millions)	2022		2021		2022		2021		(in millions)	2023		2022

Equipment & Instruments	Equipment & Instruments	$	163	$	176	$	498	$	523	Equipment & Instruments	$	152	$	166
CAD/CAM	CAD/CAM	116		147		351		403		CAD/CAM	105		106
Orthodontics	Orthodontics	76		63		220		212		Orthodontics	86		68
Implants	Implants	135		150		439		461		Implants	137		155
Healthcare	Healthcare	66		76		208		225		Healthcare	68		70
Technology & Equipment segment revenue	Technology & Equipment segment revenue	$	556	$	612	$	1,716	$	1,824	Technology & Equipment segment revenue	$	548	$	565

Endodontic & Restorative	Endodontic & Restorative	$	282	$	313	$	887	$	953	Endodontic & Restorative	$	313	$	293
Other Consumables	Other Consumables	109		115		336		351		Other Consumables	117		111
Consumables segment revenue	Consumables segment revenue	$	391	$	428	$	1,223	$	1,304	Consumables segment revenue	$	430	$	404

Total net sales	Total net sales	$	947	$	1,040	$	2,939	$	3,128	Total net sales	$	978	$	969

Net sales disaggregated by geographic region for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


		Three Months Ended				Nine Months Ended					Three Months Ended
(in millions)	(in millions)	2022		2021		2022		2021		(in millions)		2023		2022

United States	United States	$	357	$	384	$	1,023	$	1,094	United States		$	351	$	308
Europe	Europe	358		393		1,183		1,239		Europe		396		411
Rest of World	Rest of World	232		263		733		795		Rest of World		231		250

Total net sales	Total net sales	$	947	$	1,040	$	2,939	$	3,128	Total net sales		$	978	$	969

Contract Assets and Liabilities

The Company ~~normally~~ does not typically have contract assets in the normal course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had ~~$74~~$93 million and ~~$68~~$84 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. The Company recognized approximately $32 million of revenue during the current year which was previously deferred as of December 31, ~~2021 of approximately $48 million during the current year.~~2022. The Company expects to recognize ~~significantly all~~a significant majority of the remaining deferred revenue within the next twelve months.

Allowance for Doubtful Accounts

Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $9$11 million at ~~September 30, 2022~~March 31, 2023 and ~~$13~~$14 million at December 31, ~~2021.~~2022. For the three months ended March 31, 2023 and ~~nine months ended September 30,~~ 2022, ~~and 2021,~~ changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.

1410

NOTE 3 – STOCK COMPENSATION

The amounts of stock compensation expense recorded in the Company's Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


		Three Months Ended				Nine Months Ended					Three Months Ended
(in millions)	(in millions)	2022		2021		2022		2021		(in millions)	2023		2022

Cost of products sold	Cost of products sold	$	1	$	2	$	2	$	4	Cost of products sold	$	1	$	1
Selling, general, and administrative expense	Selling, general, and administrative expense	12		19		43		48		Selling, general, and administrative expense	13		9
Research and development expense	Research and development expense	1		1		2		2		Research and development expense	1		1
Restructuring and other costs										Restructuring and other costs	2		—
Total stock based compensation expense	Total stock based compensation expense	$	14	$	22	$	47	$	54	Total stock based compensation expense	$	17	$	11

Related deferred income tax benefit	Related deferred income tax benefit	$	1	$	2	$	4	$	6	Related deferred income tax benefit	$	2	$	1

1511

NOTE 4 – COMPREHENSIVE INCOME (LOSS)

Changes in Accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the ~~nine~~three months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:

(in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total
Balance, net of tax, at December 31, 2021 $ (366) $ (16) $ (103) $ (107) $ (592)
Other comprehensive (loss) income before reclassifications and tax impact (37) 3 9 — (25)
Tax expense (11) — (1) — (12)
Other comprehensive (loss) income, net of tax, before reclassifications (48) 3 8 — (37)
Amounts reclassified from accumulated other comprehensive income, net of tax — (1) — 1 —
Net (decrease) increase in other comprehensive income (48) 2 8 1 (37)
Balance, net of tax, at March 31, 2022 $ (414) $ (14) $ (95) $ (106) $ (629)
Other comprehensive (loss) income before reclassifications and tax impact (86) (3) 32 — (57)
Tax expense (28) — (8) — (36)
Other comprehensive (loss) income, net of tax, before reclassifications (114) (3) 24 — (93)
Amounts reclassified from accumulated other comprehensive income, net of tax — 1 — 2 3
Net (decrease) increase in other comprehensive income (114) (2) 24 2 (90)
Balance, net of tax, at June 30, 2022 $ (528) $ (16) $ (71) $ (104) $ (719)
Other comprehensive (loss) income before reclassifications and tax impact (120) 3 28 — (89)
Tax expense (28) (1) (7) — (36)
Other comprehensive (loss) benefit, net of tax, before reclassifications (148) 2 21 — (125)
Amounts reclassified from accumulated other comprehensive income, net of tax — (1) — 1 —
Net (decrease) increase in other comprehensive income (148) 1 21 1 (125)
Balance, net of tax, at September 30, 2022 $ (676) $ (15) $ (50) $ (103) $ (844)



(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2022	$	(522)	$	(17)	$	(73)	$	(16)	$	(628)
Other comprehensive income (loss) before reclassifications and tax impact	6		(1)		—		—		5
Tax benefit	9		—		—		—		9
Other comprehensive income (loss), net of tax, before reclassifications	15		(1)		—		—		14
Amounts reclassified from accumulated other comprehensive income, net of tax	—		—		—		—		—
Net increase (decrease) in other comprehensive income	15		(1)		—		—		14


Balance, net of tax, at March 31, 2023	$	(507)	$	(18)	$	(73)	$	(16)	$	(614)


(in millions)	(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total		(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2020		$	(187)	$	(25)	$	(119)	$	(133)	$	(464)
Other comprehensive (loss) income before reclassifications and tax impact		(74)		(6)		9		3		(68)
Tax (expense) benefit		(25)		2		(2)		(1)		(26)
Other comprehensive (loss) income, net of tax, before reclassifications		(99)		(4)		7		2		(94)
Amounts reclassified from accumulated other comprehensive income, net of tax		—		2		—		2		4
Net (decrease) increase in other comprehensive income		(99)		(2)		7		4		(90)
Balance, net of tax, at March 31, 2021		$	(286)	$	(27)	$	(112)	$	(129)	$	(554)
Other comprehensive income before reclassifications and tax impact		31		3		1		—		35
Tax benefit (expense)		6		(2)		(1)		—		3
Other comprehensive income, net of tax, before reclassifications		37		1		—		—		38
Amounts reclassified from accumulated other comprehensive income, net of tax		—		3		—		2		5
Net increase in other comprehensive income		37		4		—		2		43

Balance, net of tax, at June 30, 2021		$	(249)	$	(23)	$	(112)	$	(127)	$	(511)
Balance, net of tax, at December 31, 2021												Balance, net of tax, at December 31, 2021	$	(366)	$	(16)	$	(103)	$	(107)	$	(592)
Other comprehensive (loss) income before reclassifications and tax impact	Other comprehensive (loss) income before reclassifications and tax impact	(59)		6		3		—		(50)		Other comprehensive (loss) income before reclassifications and tax impact	(37)		3		9		—		(25)
Tax expense	Tax expense	(9)		(1)		(1)		—		(11)		Tax expense	(11)		—		(1)		—		(12)
Other comprehensive (loss) income, net of tax, before reclassifications	Other comprehensive (loss) income, net of tax, before reclassifications	(68)		5		2		—		(61)		Other comprehensive (loss) income, net of tax, before reclassifications	(48)		3		8		—		(37)
Amounts reclassified from accumulated other comprehensive income, net of tax	Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		2		5		Amounts reclassified from accumulated other comprehensive income, net of tax	—		(1)		—		1		—
Net (decrease) increase in other comprehensive income	Net (decrease) increase in other comprehensive income	(68)		8		2		2		(56)		Net (decrease) increase in other comprehensive income	(48)		2		8		1		(37)
Balance, net of tax, at September 30, 2020		$	(317)	$	(15)	$	(110)	$	(125)	$	(567)
Balance, net of tax, at March 31, 2022												Balance, net of tax, at March 31, 2022	$	(414)	$	(14)	$	(95)	$	(106)	$	(629)

At ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, the cumulative tax adjustments were ~~$84~~$109 million and ~~$168~~$100 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of ~~$639~~$417 million and ~~$250~~$438 million at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively, and cumulative losses on loans designated as hedges of net investments of ~~$37~~$90 million and ~~$116~~$84 million, respectively. These foreign currency translation losses were partially offset by movements on derivative financial instruments.

Reclassifications out of AOCI to the Consolidated Statements of Operations for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were not significant.

1712

NOTE 5 – EARNINGS PER COMMON SHARE

The computation of basic and diluted (loss) earnings per common share for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


Basic Earnings Per Common Share		Three Months Ended				Nine Months Ended
Basic (Loss) Earnings Per Common Share										Basic (Loss) Earnings Per Common Share	Three Months Ended
(in millions, except per share amounts)	(in millions, except per share amounts)	2022		2021		2022		2021		(in millions, except per share amounts)	2023		2022

Net (loss) income attributable to Dentsply Sirona	Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292	Net (loss) income attributable to Dentsply Sirona	$	(19)	$	69

Weighted average common shares outstanding	Weighted average common shares outstanding	214.9		218.6		215.6		218.6		Weighted average common shares outstanding	214.5		217.0

(Loss) earnings per common share - basic	(Loss) earnings per common share - basic	$	(5.01)	$	0.39	$	(4.34)	$	1.34	(Loss) earnings per common share - basic	$	(0.09)	$	0.32

Diluted Earnings Per Common Share		Three Months Ended				Nine Months Ended
Diluted (Loss) Earnings Per Common Share										Diluted (Loss) Earnings Per Common Share	Three Months Ended
(in millions, except per share amounts)	(in millions, except per share amounts)	2022		2021		2022		2021		(in millions, except per share amounts)	2023		2022

Net (loss) income attributable to Dentsply Sirona	Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292	Net (loss) income attributable to Dentsply Sirona	$	(19)	$	69

Weighted average common shares outstanding	Weighted average common shares outstanding	214.9		218.6		215.6		218.6		Weighted average common shares outstanding	214.5		217.0
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		1.9		—		2.1		Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		0.8
Total weighted average diluted shares outstanding	Total weighted average diluted shares outstanding	214.9		220.5		215.6		220.7		Total weighted average diluted shares outstanding	214.5		217.8

(Loss) earnings per common share - diluted	(Loss) earnings per common share - diluted	$	(5.01)	$	0.38	$	(4.34)	$	1.32	(Loss) earnings per common share - diluted	$	(0.09)	$	0.32

The calculation of weighted average diluted common shares outstanding excluded ~~0.3 million and 0.5~~1.4 million of potentially ~~diluted~~dilutive common shares because the Company reported a net loss for the three months ended ~~and nine months ended September 30, 2022, respectively.~~March 31, 2023.

For the three ~~and nine~~ months ended ~~September 30, 2022,~~March 31, 2023, the Company excluded from the computation of weighted average diluted shares outstanding ~~3.6~~3.8 million of equivalent shares of common stock from stock options and RSUs because their effect would be antidilutive. For the three ~~and nine~~ months ended ~~September 30, 2021,~~March 31, 2022, the Company excluded ~~0.9 million and 0.9~~1.9 million of equivalent shares of common stock outstanding from stock options and RSUs ~~respectively,~~ because their effect would be antidilutive.

The Board of Directors has approved a share repurchase program, of up to $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. At ~~September 30, 2022,~~March 31, 2023, the Company had authorization to repurchase ~~$740~~$620 million in shares of common stock remaining under the share repurchase program.

On March ~~8, 2022,~~3, 2023, the Company entered into an Accelerated Share Repurchase Agreement ("ASR Agreement") with a financial institution to ~~purchase~~repurchase the Company's common ~~stock~~stock. The Company repurchased shares under the ASR Agreement as part of the share repurchase program described above. The final number of shares will be based on the volume-weighted average price of the Company's common stock during the ~~term~~valuation period of the ~~agreement,~~ASR Agreement, less a ~~discount.~~discount and subject to adjustments.


(in millions, except per share amounts)	(in millions, except per share amounts)			Initial Delivery					Final Settlement				(in millions, except per share amounts)			Initial Delivery					Final Settlement
Agreement Date	Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share		Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
March 8, 2022		$	150	2.4	$	50.44	80	%	April 19, 2022	3.1	$	48.22
March 3, 2023													March 3, 2023	$	150	3.1	$	38.74	80	%	April 28, 2023	3.9	$	38.55

1813

The ASR ~~agreement~~Agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March ~~9, 2022~~6, 2023 of ~~$120~~$121 million and a forward contract indexed to the Company's common stock for an amount of common shares to be determined on the final settlement date. This initial treasury stock transaction included an excise tax accrual of $1 million for public company stock repurchases established by the Inflation Reduction Act (IRA) of 2022. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument. Therefore, the forward contract was recorded as Capital in excess of par value ~~and upon final settlement was recorded as Treasury Stock~~ in the Consolidated Balance Sheets at ~~September 30, 2022.~~March 31, 2023. The initial delivery ~~and final settlement~~ of common stock reduced the weighted average common shares outstanding for both basic and diluted EPS. The forward contract did not impact the weighted average common shares outstanding for diluted EPS.

1914

~~NOTE 6 – BUSINESS COMBINATIONS~~

~~Acquisitions~~

~~2021 Transactions~~

On July 1, 2021, the effective date of the transaction, the Company paid $7 million to acquire the remaining interest in the dental business of a partially owned affiliate based in Switzerland that primarily develops highly specialized software with a focus on CAD/CAM systems. The acquisition is expected to further accelerate the development of the Company's specialized software related to CAD/CAM systems.

The fair values of the assets acquired and liabilities assumed in connection with the acquisition of the affiliate included $4 million of Other current assets, $3 million of Intangible assets, $2 million of Current Liabilities and $1 million of Other long-term liabilities. The cash paid and the $4 million fair value of the previously-held interest in the entity prior to the acquisition has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $7 million in goodwill. This goodwill is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations, and is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $2 million.

~~Identifiable intangible assets acquired were as follows:~~

~~Weighted Average~~

~~Useful Life~~

~~(in millions, except for useful life)~~

~~Amount~~

~~(in years)~~

~~In-process R&D~~

~~Indefinite~~

On June 1, 2021, the effective date of the transaction, the Company paid $132 million to acquire substantially all of the assets of Propel Orthodontics LLC and certain of its affiliated entities, a privately-held business based in California ("Propel Orthodontics"). The acquired business manufactures and sells orthodontic devices and provides in-office and at-home orthodontic accessory devices to orthodontists and their patients primarily within the clear aligner market. The acquisition is expected to further accelerate the growth and profitability of the Company's combined clear aligners business.

~~The fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows:~~


~~(in millions)~~


~~Other current assets~~	$	4
~~Intangible assets~~	66
~~Current liabilities~~	~~(1)~~
~~Net assets acquired~~	69
~~Goodwill~~	63
~~Purchase consideration~~	$	~~132~~

The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $63 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations. The goodwill is expected to be deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in a reduction to goodwill of $2 million.

~~Identifiable intangible assets acquired were as follows:~~

Weighted Average
Useful Life
(in millions, except for useful life) Amount (in years)
Developed technology $ 66 10

On January 21, 2021, the effective date of the transaction, the Company paid $94 million with the potential for additional earn-out provision payments of up to $10 million, to acquire 100% of the outstanding shares of Datum Dental, Ltd. ("Datum"), a privately-held producer and distributor of specialized regenerative dental material based in Israel. The fair value of the earn-out provision has been valued at $9 million as of the transaction date, resulting in a total purchase price of $103 million.

~~The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows:~~


~~(in millions)~~

~~Cash and cash equivalents~~	$	2
~~Other current assets~~	2
~~Intangible assets~~	76
~~Current liabilities~~	~~(2)~~
~~Other long-term assets (liabilities), net~~	~~(14)~~
~~Net assets acquired~~	64
~~Goodwill~~	39
~~Purchase consideration~~	$	~~103~~

The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $39 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations. The goodwill is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $6 million.

~~Identifiable intangible assets acquired were as follows:~~

Weighted Average
Useful Life
(in millions, except for useful life) Amount (in years)
Developed technology $ 66 15
In-process R&D 10 Indefinite
Total $ 76

In the nine months ended September 30, 2022, certain earn-out provisions were achieved and the Company made cash payments of $5 million to the former shareholders of Datum with no impact to the Company's Statement of Operations for the period. As of September 30, 2022, the remaining contingent consideration obligation was $4 million.

The results of operations for each of the acquired businesses above upon the effective date of each transaction have been included in the accompanying financial statements. These results, as well as the historical results for the above acquired businesses for the periods ended September 30, 2022 and September 30, 2021, are not material in relation to the Company’s net sales and earnings for those periods. The Company therefore does not believe these acquisitions represent material transactions either individually or in the aggregate requiring the supplemental pro-forma information prescribed by ASC 805 and accordingly, this information is not presented.

~~Investment in Affiliates~~

On June 4, 2021, the effective date of the transaction, the Company paid $16 million to acquire a minority interest in a U.K.-based, privately-held provider of healthcare consumables. The investment is recorded as an equity method investment within Other noncurrent assets in the Consolidated Balance Sheets.

~~Divestitures~~

On April 1, 2021, the Company disposed of certain orthodontics businesses based in Japan previously included as part of the Technologies & Equipment segment in exchange for a cash receipt of $8 million. The divestiture resulted in an immaterial loss recorded in Other expense (income), net in the Consolidated Statements of Operations for the nine months ended September 30, 2021.

On February 1, 2021, the Company disposed of an investment casting business previously included as part of the Consumables segment in exchange for a cash receipt of $19 million. The divestiture resulted in a pre-tax gain of $13 million recorded in Other expense (income), net in the Consolidated Statements of Operations for the nine months ended September 30, 2021.

NOTE 76 – SEGMENT INFORMATION

The Company’s two operating segments are organized primarily by product and generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating segments are also the Company’s reportable segments in accordance with how the Company’s chief operating decision-maker regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources.

The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs (including certain inter-segment eliminations which are generally based on estimated external selling prices and are eliminated during consolidation), goodwill ~~impairments,~~and intangible asset impairments, restructuring and other costs, interest expense, net, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions.

A description of the products and services provided within each of the Company’s two reportable segments is provided below.

Technologies & Equipment

This segment is responsible for the design, manufacture, and sales of the Company’s dental technology and equipment products and healthcare products. These products include dental implants, CAD/CAM systems, orthodontic ~~clear~~ aligners, imaging systems, treatment centers, instruments, as well as medical devices.

Consumables

This segment is responsible for the design, manufacture, and sales of the Company’s consumable products which include various preventive, restorative, endodontic, and dental laboratory products.

The Company’s segment information for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ was as follows:

Net Sales


		Three Months Ended				Nine Months Ended					Three Months Ended
(in millions)	(in millions)	2022		2021		2022		2021		(in millions)	2023		2022

Technologies & Equipment	Technologies & Equipment	$	556	$	612	$	1,716	$	1,824	Technologies & Equipment	$	548	$	565
Consumables	Consumables	391		428		1,223		1,304		Consumables	430		404
Total net sales	Total net sales	$	947	$	1,040	$	2,939	$	3,128	Total net sales	$	978	$	969

Segment Adjusted Operating Income


		Three Months Ended				Nine Months Ended					Three Months Ended
(in millions)	(in millions)	2022		2021		2022		2021		(in millions)	2023		2022

Technologies & Equipment	Technologies & Equipment	$	73	$	134	$	278	$	391	Technologies & Equipment	$	67	$	86
Consumables	Consumables	121		123		398		426		Consumables	131		135
Segment adjusted operating income	Segment adjusted operating income	194		257		676		817		Segment adjusted operating income	198		221

Reconciling items expense (income):	Reconciling items expense (income):									Reconciling items expense (income):
All other (a)	All other (a)	77		67		223		199		All other (a)	87		65
Goodwill impairment		1,187		—		1,187		—
Intangible asset impairment and other costs		97		3		107		11

Restructuring and other costs										Restructuring and other costs	59		3
Interest expense, net	Interest expense, net	14		14		41		43		Interest expense, net	19		12

Other expense (income), net	Other expense (income), net	9		5		20		4		Other expense (income), net	7		(2)
Amortization of intangible assets	Amortization of intangible assets	51		56		159		167		Amortization of intangible assets	53		55
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	—		(1)		2		4		Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	1		1
(Loss) income before income taxes	(Loss) income before income taxes	$	(1,241)	$	113	$	(1,063)	$	389	(Loss) income before income taxes	$	(28)	$	87

(a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.

2315

NOTE 87 – INVENTORIES

Inventories, net were as follows:


(in millions)	(in millions)	September 30, 2022		December 31, 2021		(in millions)	March 31, 2023		December 31, 2022

Raw materials and supplies	Raw materials and supplies	$	142	$	139	Raw materials and supplies	$	168	$	169
Work-in-process	Work-in-process	70		72		Work-in-process	87		77
Finished goods	Finished goods	380		304		Finished goods	404		381
Inventories, net	Inventories, net	$	592	$	515	Inventories, net	$	659	$	627

The Company's inventory reserve was ~~$77~~$90 million and ~~$86~~$83 million at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. Inventories are stated at the lower of cost and net realizable value.

NOTE 98 – ~~INTANGIBLE ASSET IMPAIRMENT~~RESTRUCTURING AND OTHER COSTS

~~Intangible asset impairment~~Restructuring and other costs for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were recorded in the Consolidated Statements of Operations as follows:

Affected Line Item in the Consolidated Statements of Operations Three Months Ended Nine Months Ended
(in millions) 2022 2021 2022 2021
Cost of products sold $ — $ — $ — $ (3)
Selling, general, and administrative expenses — 3 — 6
Intangible asset impairment and other costs 97 3 107 11
Total intangible asset impairment and other costs $ 97 $ 6 $ 107 $ 14


Affected Line Item	Three Months Ended
(in millions)	2023		2022

Cost of products sold	$	4	$	—

Restructuring and other costs	59		3

Total restructuring and other costs	$	63	$	3

~~For~~The restructuring and other costs of $59 million recorded in the ~~three~~first quarter of 2023 consist primarily of employee severance benefits and ~~nine months ended September 30, 2022, the above~~other restructuring costs ~~include an impairment charge of $94 million~~ related to ~~indefinite-lived tradenames~~the plan approved by the Board of Directors of the Company on February 14, 2023. This plan seeks to restructure the Company’s business to improve operational performance and ~~trademarks within~~drive shareholder value creation through a new operating model with five global business units, optimization of central functions and overall management infrastructure, and other efforts aimed at cost savings. The restructuring plan anticipates a reduction in the ~~Technologies & Equipment segment~~Company’s global workforce of approximately 8% to 10%, subject to co-determination processes with employee representative groups in countries where required. The Company expects to incur between $115 and $135 million in one-time charges, comprising $80 to $100 million in restructuring expenditures and charges, primarily related to employee transition, severance payments, employee benefits and facility closure costs, and $35 million in other non-recurring costs which mostly consist of legal, consulting and other professional service fees. The majority of these costs will be incurred as cash expenditures in 2023. The estimates of these charges and their timing are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the ~~Consumables segment. For more information on~~Company may incur other charges or cash expenditures in connection with this ~~impairment charge, refer to Note 14 Goodwill and Intangible Assets.~~plan which are not currently contemplated.

~~Other costs for these periods include severance and other expense related to~~The liabilities associated with the Company's restructuring ~~plans. The~~plans are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. Activity in the Company’s restructuring accruals at ~~September 30, 2022 were~~March 31, 2023 was as follows:


		Severance									Severance
(in millions)	(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total		(in millions)	2022 and Prior Plans		2023 Plan		Total

Balance at December 31, 2021		$	5	$	9	$	—	$	14
Balance at December 31, 2022										Balance at December 31, 2022	$	7	$	—	$	7
Provisions	Provisions	1		1		8		10		Provisions	2		53		55
Amounts applied	Amounts applied	(3)		(5)		(3)		(11)		Amounts applied	(2)		(5)		(7)
Change in estimates		(1)		—		—		(1)
Balance at September 30, 2022		$	2	$	5	$	5	$	12

Balance at March 31, 2023										Balance at March 31, 2023	$	7	$	48	$	55


		Other Restructuring Costs									Other Restructuring Costs
(in millions)	(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total		(in millions)	2022 and Prior Plans		2023 Plan		Total

Balance at December 31, 2021		$	4	$	—	$	—	$	4
Balance at December 31, 2022										Balance at December 31, 2022	$	1	$	—	$	1
Provisions	Provisions	1		1		1		3		Provisions	—		4		4
Amounts applied	Amounts applied	(4)		(1)		(1)		(6)		Amounts applied	—		(4)		(4)

Balance at September 30, 2022		$	1	$	—	$	—	$	1
Balance at March 31, 2023										Balance at March 31, 2023	$	1	$	—	$	1

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	(in millions)	December 31, 2021		Provisions		Amounts Applied		Change in Estimates		September 30, 2022		(in millions)	December 31, 2022		Provisions		Amounts Applied		March 31, 2023

Technologies & Equipment	Technologies & Equipment	$	7	$	3	$	(6)	$	—	$	4	Technologies & Equipment	$	2	$	28	$	—	$	30
Consumables	Consumables	11		7		(8)		(1)		9		Consumables	6		24		(4)		26
All Other	All Other	—		3		(3)		—		—		All Other	—		7		(7)		—
Total	Total	$	18	$	13	$	(17)	$	(1)	$	13	Total	$	8	$	59	$	(11)	$	56

~~The associated restructuring liabilities are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets.~~

2518

NOTE 109 – FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes.

The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at ~~September 30, 2022~~March 31, 2023 and the notional amounts expected to mature during the next 12 months.


(in millions)	(in millions)	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months		(in millions)	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

Cash Flow Hedges	Cash Flow Hedges					Cash Flow Hedges
Foreign exchange forward contracts	Foreign exchange forward contracts	$	85	$	79	Foreign exchange forward contracts	$	131	$	94

Total derivative instruments designated as cash flow hedges	Total derivative instruments designated as cash flow hedges	$	85	$	79	Total derivative instruments designated as cash flow hedges	$	131	$	94

Hedges of Net Investments	Hedges of Net Investments					Hedges of Net Investments
Foreign exchange forward contracts	Foreign exchange forward contracts	$	157	$	78	Foreign exchange forward contracts	$	173	$	87
Cross currency basis swaps	Cross currency basis swaps	262		—		Cross currency basis swaps	289		—
Total derivative instruments designated as hedges of net investments	Total derivative instruments designated as hedges of net investments	$	419	$	78	Total derivative instruments designated as hedges of net investments	$	462	$	87

Fair Value Hedges	Fair Value Hedges					Fair Value Hedges
Interest rate swaps	Interest rate swaps	$	250	$	—	Interest rate swaps	$	250	$	—
Foreign exchange forward contracts	Foreign exchange forward contracts	128		49		Foreign exchange forward contracts	92		79
Total derivative instruments designated as fair value hedges	Total derivative instruments designated as fair value hedges	$	378	$	49	Total derivative instruments designated as fair value hedges	$	342	$	79

Derivative Instruments not Designated as Hedges	Derivative Instruments not Designated as Hedges					Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	Foreign exchange forward contracts	$	27	$	27	Foreign exchange forward contracts	$	527	$	527
Total derivative instruments not designated as hedges	Total derivative instruments not designated as hedges	$	27	$	27	Total derivative instruments not designated as hedges	$	527	$	527

Cash Flow Hedges

Foreign Exchange Risk Management

The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions.

2619

Interest Rate Risk Management

The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

On May 26, 2020, the Company paid $31 million to settle the $150 million notional T-Lock contract, which partially hedged the interest rate risk of the $750 million senior unsecured notes. This loss is amortized over the ten-year life of the notes. As of ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021, $23~~2022, $22 million and ~~$25~~$23 million, respectively, of this loss is remaining to be amortized from AOCI in future periods.

AOCI Release

Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At ~~September 30, 2022,~~March 31, 2023, the Company expects to reclassify ~~an immaterial amount~~$4 million of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 4, Comprehensive Income (Loss).

Hedges of Net Investments in Foreign Operations

The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments and are included in AOCI. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, ~~cross-currency swap basis rates~~ and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

On July 2, 2021, the Company entered into a cross currency basis swap totaling a notional amount of $300 million which matures on June 3, 2030. The cross currency basis swap is designated as a hedge of net investments. This contract effectively ~~converts~~converted a portion of the $750 million bond coupon from 3.3% to 1.7%.

On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023. The Company enters into additional foreign exchange contracts as individual contracts within the portfolio mature. As of ~~September 30, 2022,~~March 31, 2023, the euro net investment hedge portfolio has an aggregate notional value of 160 million euro with maturity dates through ~~September 2024.~~March 2025.

2720

Fair Value Hedges

Foreign Exchange Risk Management

The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

On January 6, 2021 the Company entered into foreign exchange forward contracts with a notional value of 1.3 billion Swedish kroner as a result of an increase in intercompany loans denominated in Swedish kronor. The foreign exchange forwards are designated as fair value hedges.

Interest Rate Risk Management

On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively ~~convert~~converted a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term of five-years maturing on June 1, 2026 and $150 million has a term of nine years maturing on March 1, 2030.

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in operating activities in the Consolidated Statements of Cash Flows.

Gains and (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three ~~and nine~~ months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were not significant.

2821

Derivative Instrument Activity

The ~~amount~~effect of ~~gains and losses recorded in~~derivative hedging instruments on the ~~Company's~~ Consolidated ~~Balance Sheets~~Statements of Operations and Consolidated Statements of ~~Operations related to all derivative instruments~~Comprehensive Income (Loss) for the three months ended ~~September 30,~~March 31, 2023 and 2022 ~~and 2021~~ were as follows:


		Three Months Ended September 30, 2022							Three Months Ended March 31, 2023								Three Months Ended March 31, 2022
(in millions)	(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)			(in millions)	Cost of products sold		Interest expense, net		Other expense (income), net			Cost of products sold		Interest expense, net		Other expense (income), net

Cash Flow Hedges
Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded										Total amounts of line items presented in the Statement of Operations in which the effects of cash flow, net investment or fair value hedges are recorded	$	459	$	19	$	7		$	448	$	12	$	(2)

(Gain) loss on Cash Flow Hedges reclassified from AOCI into income										(Gain) loss on Cash Flow Hedges reclassified from AOCI into income
Foreign exchange forward contracts	Foreign exchange forward contracts	$	3	Cost of products sold	$	1	$	—		Foreign exchange forward contracts	$	(1)	$	—	$	—		$	—	$	—	$	—
Interest rate swaps	Interest rate swaps	—		Interest expense, net	—		—			Interest rate swaps	—		1		—			—		1		—

Total for cash flow hedging		$	3		$	1	$	—

Hedges of Net Investments
(Gain) loss on Hedges of Net Investment										(Gain) loss on Hedges of Net Investment
Cross currency basis swaps	Cross currency basis swaps	$	18	Interest expense, net	$	—	$	2		Cross currency basis swaps	$	—	$	1	$	—		$	—	$	—	$	—

Foreign exchange forward contracts	Foreign exchange forward contracts	11		Other expense (income), net	—		—			Foreign exchange forward contracts	—		—		1			—		(1)		—

Total for net investment hedging		$	29		$	—	$	2

Fair Value Hedges
(Gain) loss on Fair Value Hedges:										(Gain) loss on Fair Value Hedges:
Interest rate swaps	Interest rate swaps	$	—	Interest expense, net	$	—	$	(1)		Interest rate swaps	$	—	$	2	$	—		$	—	$	(1)	$	—
Foreign exchange forward contracts	Foreign exchange forward contracts	(1)		Other expense (income), net	—		13			Foreign exchange forward contracts	—		—		—			—		—		(8)

Total for fair value hedging		$	(1)		$	—	$	12


										Amount of Gain or (Loss) Recognized in AOCI						Amount of Gain or (Loss) Reclassified from AOCI into Income
		Three Months Ended September 30, 2021								Three months ended March 31,				Consolidated Statements of Operations Location		Three months ended March 31,
(in millions)	(in millions)	Gain (Loss) Recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)		(in millions)	2023		2022			2023					2022

Cash Flow Hedges	Cash Flow Hedges								Cash Flow Hedges
Foreign exchange forward contracts	Foreign exchange forward contracts	$	6	Cost of products sold	$	(2)	$	—	Foreign exchange forward contracts	$	(1)	$	3		Cost of products sold			$	1				$	—
Interest rate swaps	Interest rate swaps	—		Interest expense, net	(1)		—		Interest rate swaps	—		—		Interest expense, net		(1)					(1)

Total for cash flow hedging		$	6		$	(3)	$	—

Hedges of Net Investments	Hedges of Net Investments								Hedges of Net Investments
Cross currency basis swaps	Cross currency basis swaps	$	(1)	Interest expense, net	$	—	$	1	Cross currency basis swaps	$	1	$	8	Interest expense, net		$	—				$	—

Foreign exchange forward contracts	Foreign exchange forward contracts	4		Other expense (income), net	—		—		Foreign exchange forward contracts	(2)		3		Other expense (income), net		—					—

Total for net investment hedging		$	3		$	—	$	1

Fair Value Hedges	Fair Value Hedges								Fair Value Hedges
Interest rate swaps									Interest rate swaps	$	—	$	—	Interest expense, net		$	—				$	—
Foreign exchange forward contracts	Foreign exchange forward contracts	$	—	Interest expense, net	$	—	$	6	Foreign exchange forward contracts	1		(2)		Other expense (income), net		—					—
Interest rate swaps		—		Cost of products sold	—		1
Total for fair value hedging		$	—		$	—	$	7

2922

The amount of gains and losses recorded in the Company's Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments for the nine months ended September 30, 2022 and 2021 were as follows:

Nine Months Ended September 30, 2022
(in millions) Gain (Loss) recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense)
Cash Flow Hedges
Foreign exchange forward contracts $ 3 Cost of products sold $ 3 $ —
Interest rate swaps — Interest expense, net (2) —
Total for cash flow hedging $ 3 $ 1 $ —
Hedges of Net Investments
Cross currency basis swaps $ 47 Interest expense, net $ — $ 4
Foreign exchange forward contracts 24 Other expense (income), net — 1
Total for net investment hedging $ 71 $ — $ 5
Fair Value Hedges
Interest rate swaps $ — Interest expense, net $ — $ —
Foreign exchange forward contracts (2) Other expense (income), net — 37
Total for fair value hedging $ (2) $ — $ 37

Nine Months Ended September 30, 2021
(in millions) Gain (Loss) recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense)
Cash Flow Hedges
Foreign exchange forward contracts $ 3 Cost of products sold $ (4) $ 1
Interest rate swaps — Interest expense, net (4) —
Total for cash flow hedging $ 3 $ (8) $ 1
Hedges of Net Investments
Cross currency basis swaps $ 6 Interest expense, net $ — $ 5
Foreign exchange forward contracts 7 Other expense (income), net — —
Total for net investment hedging $ 13 $ — $ 5
Fair Value Hedges
Interest rate swaps $ — Interest expense, net $ — $ 1
Foreign exchange forward contracts — Other expense (income), net — 18
Total for fair value hedging $ — $ — $ 19

Consolidated Balance Sheets Location of Derivative Fair Values

The fair value and the location of the Company's derivatives in the Consolidated Balance Sheets were as follows:


		September 30, 2022									March 31, 2023
(in millions)	(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities		(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:	Designated as Hedges:									Designated as Hedges:
Foreign exchange forward contracts	Foreign exchange forward contracts	$	37	$	29	$	2	$	3	Foreign exchange forward contracts	$	28	$	—	$	4	$	3
Interest rate swaps	Interest rate swaps	—		—		9		27		Interest rate swaps	—		—		10		19
Cross currency basis swaps	Cross currency basis swaps	3		40		—		—		Cross currency basis swaps	3		24		—		—
Total	Total	$	40	$	69	$	11	$	30	Total	$	31	$	24	$	14	$	22

Not Designated as Hedges:	Not Designated as Hedges:									Not Designated as Hedges:
Foreign exchange forward contracts	Foreign exchange forward contracts	$	4	$	—	$	3	$	—	Foreign exchange forward contracts	$	3	$	—	$	4	$	—
Total	Total	$	4	$	—	$	3	$	—	Total	$	3	$	—	$	4	$	—

		December 31, 2021									December 31, 2022
(in millions)	(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities		(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:	Designated as Hedges:									Designated as Hedges:
Foreign exchange forward contracts	Foreign exchange forward contracts	$	18	$	11	$	2	$	1	Foreign exchange forward contracts	$	32	$	3	$	5	$	2
Interest rate swaps	Interest rate swaps	5		—		—		9		Interest rate swaps	—		—		9		25
Cross currency basis swaps	Cross currency basis swaps	4		—		—		7		Cross currency basis swaps	4		22		—		—
Total	Total	$	27	$	11	$	2	$	17	Total	$	36	$	25	$	14	$	27

Not Designated as Hedges:	Not Designated as Hedges:									Not Designated as Hedges:
Foreign exchange forward contracts	Foreign exchange forward contracts	$	1	$	—	$	1	$	—	Foreign exchange forward contracts	$	3	$	—	$	5	$	—
Total	Total	$	1	$	—	$	1	$	—	Total	$	3	$	—	$	5	$	—

Balance Sheet Offsetting

Substantially all of the Company’s derivative contracts are subject to netting ~~arrangements;~~arrangements, whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

3123

Offsetting of financial assets and liabilities under netting arrangements at ~~September 30, 2022~~March 31, 2023 were as follows:


								Gross Amounts Not Offset in the Consolidated Balance Sheets													Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount		(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets	Assets													Assets
Foreign exchange forward contracts	Foreign exchange forward contracts	$	70	$	—	$	70	$	(6)	$	—	$	64	Foreign exchange forward contracts	$	31	$	—	$	31	$	(5)	$	—	$	26

Cross currency basis swaps	Cross currency basis swaps	43		—		43		(17)		—		26		Cross currency basis swaps	27		—		27		(13)		—		14

Total assets	Total assets	$	113	$	—	$	113	$	(23)	$	—	$	90	Total assets	$	58	$	—	$	58	$	(18)	$	—	$	40

Liabilities	Liabilities													Liabilities
Foreign exchange forward contracts	Foreign exchange forward contracts	$	8	$	—	$	8	$	(8)	$	—	$	—	Foreign exchange forward contracts	$	11	$	—	$	11	$	(9)	$	—	$	2

Interest rate swaps	Interest rate swaps	36		—		36		(15)		—		21		Interest rate swaps	29		—		29		(9)		—		20

Total liabilities	Total liabilities	$	44	$	—	$	44	$	(23)	$	—	$	21	Total liabilities	$	40	$	—	$	40	$	(18)	$	—	$	22

Offsetting of financial assets and liabilities under netting arrangements at December 31, ~~2021~~2022 were as follows:

Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount
Assets
Foreign exchange forward contracts $ 31 $ — $ 31 $ (9) $ — $ 22
Total assets $ 31 $ — $ 31 $ (9) $ — $ 22
Liabilities
Foreign exchange forward contracts $ 4 $ — $ 4 $ (4) $ — $ —
Interest rate swaps 4 — 4 (2) — 2
Cross currency basis swaps 4 — 4 (3) — 1
Total liabilities $ 12 $ — $ 12 $ (9) $ — $ 3



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	38	$	—	$	38	$	(7)	$	—	$	31


Cross currency basis swaps	26		—		26		(12)		—		14
Total assets	$	64	$	—	$	64	$	(19)	$	—	$	45

Liabilities
Foreign exchange forward contracts	$	12	$	—	$	12	$	(10)	$	—	$	2

Interest rate swaps	34		—		34		(9)		—		25


Total liabilities	$	46	$	—	$	46	$	(19)	$	—	$	27

3224

NOTE 1110 – FAIR VALUE MEASUREMENT

The estimated fair value and carrying value of the Company's total debt ~~including current portion,~~ was ~~$1,794~~$2,037 million and ~~$1,983~~$2,158 million, respectively, at ~~September 30, 2022.~~March 31, 2023. At December 31, ~~2021,~~2022, the estimated fair value and carrying value were ~~$2,239~~$1,769 million and ~~$2,095~~$1,944 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company’s public debt or is determined by discounting future cash flows using interest rates available at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021~~2022 to companies with similar credit ratings for issues with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.

Assets and liabilities measured at fair value on a recurring basis

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:


		September 30, 2022									March 31, 2023
(in millions)	(in millions)	Total		Level 1		Level 2		Level 3		(in millions)	Total		Level 1		Level 2		Level 3

Assets	Assets									Assets

Cross currency basis swaps	Cross currency basis swaps	$	43	$	—	$	43	$	—	Cross currency basis swaps	$	27	$	—	$	27	$	—
Foreign exchange forward contracts	Foreign exchange forward contracts	70		—		70		—		Foreign exchange forward contracts	31		—		31		—
Long-term debt		36		—		36		—

Total assets	Total assets	$	149	$	—	$	149	$	—	Total assets	$	58	$	—	$	58	$	—

Liabilities	Liabilities									Liabilities
Interest rate swaps	Interest rate swaps	$	36	$	—	$	36	$	—	Interest rate swaps	$	29	$	—	$	29	$	—

Foreign exchange forward contracts	Foreign exchange forward contracts	8		—		8		—		Foreign exchange forward contracts	11		—		11		—

Contingent considerations on acquisitions	Contingent considerations on acquisitions	4		—		—		4		Contingent considerations on acquisitions	4		—		—		4
Total liabilities	Total liabilities	$	48	$	—	$	44	$	4	Total liabilities	$	44	$	—	$	40	$	4


		December 31, 2021									December 31, 2022
(in millions)	(in millions)	Total		Level 1		Level 2		Level 3		(in millions)	Total		Level 1		Level 2		Level 3

Assets	Assets									Assets

Interest rate swaps		$	5	$	—	$	5	$	—

Long-term debt		4		—		4		—

Cross currency basis swaps	Cross currency basis swaps	4		—		4		—		Cross currency basis swaps	$	26	$	—	$	26	$	—
Foreign exchange forward contracts	Foreign exchange forward contracts	30		—		30		—		Foreign exchange forward contracts	38		—		38		—

Total assets	Total assets	$	43	$	—	$	43	$	—	Total assets	$	64	$	—	$	64	$	—

Liabilities	Liabilities									Liabilities
Interest rate swaps	Interest rate swaps	$	9	$	—	$	9	$	—	Interest rate swaps	$	34	$	—	$	34	$	—

Cross currency basis swaps		7		—		7		—

Foreign exchange forward contracts	Foreign exchange forward contracts	4		—		4		—		Foreign exchange forward contracts	12		—		12		—

Contingent considerations on acquisitions	Contingent considerations on acquisitions	10		—		—		10		Contingent considerations on acquisitions	4		—		—		4

Total liabilities	Total liabilities	$	30	$	—	$	20	$	10	Total liabilities	$	50	$	—	$	46	$	4

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. The Company utilizes interest rate swaps and foreign exchange forward contracts that are considered cash flow hedges. In addition, the Company at times employs certain cross currency basis swaps and forward exchange contracts that are considered hedges of net investment in foreign operations.

There have been no transfers between fair value measurement levels during the ~~nine~~three months ended ~~September 30, 2022.~~March 31, 2023.

3325

NOTE 1211 – INCOME TAXES

~~Uncertainties~~The effective tax rate for the three months ended March 31, 2023, and 2022 was 18.4% and 20.8%, respectively. The decrease in ~~Income Taxes~~the effective tax rate is primarily related to the geographic mix of revenue.

The Company recognizes the impact of a tax position in the interim consolidated financial statements if that position is "more likely than not" of being sustained on audit based on the technical merits of the position. Under ASC 740-10, the Company provides for uncertain tax positions and the related interest expense by adjusting unrecognized tax benefits and accrued interest accordingly. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense.

The Company files income tax returns in multiple jurisdictions based on its operations, some of which are under examination by taxing authorities. Certain amounts of unrecognized tax benefits may increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements, primarily due to the completion of ongoing income tax examinations. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next 12 months are not expected to be significant. Expiration of statutes of limitation in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $1 million that, if recognized, would affect the effective income tax rate.

~~Other Tax Matters~~

The impact of discrete items is separately recognized in the quarter in which they occur. During the three and nine months ended September 30, 2022, changes in tax expense for discrete tax matters was $6 million and $7 million, respectively, which are primarily composed of changes arising from income tax filings in certain jurisdictions, offset by uncertain tax positions and related interest expense. The overall tax benefit as compared to the tax expense in prior period is driven primarily by the impairment of certain goodwill and indefinite-lived intangibles. The tax benefit attributed to the impact of the impairments is $183 million. Refer to Note 14, Goodwill and Intangible Assets in Item 1 of this Form 10-Q for further discussion of the impairments.

~~During the three and nine months ended September 30, 2021, the Company recorded $4 million and $11 million, respectively, of tax expense for discrete tax matters.~~

~~U.S. Federal Legislative Changes~~

On August 16, 2022, the U.S. federal government enacted the Inflation Reduction Act of 2022. The bill includes numerous tax provisions, including a 15% corporate minimum tax as well as a 1% excise tax on share repurchases. The Company continues to evaluate the impact of this law on our operations; at this point, the legislation is not expected to have a material impact on consolidated financial statements.

3426

NOTE 1312 – FINANCING ARRANGEMENTS

At ~~September 30, 2022,~~March 31, 2023, the Company had ~~$503~~$433 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit facility.

The Company has a $500 million commercial paper program. The Company had outstanding borrowings of ~~$224~~$294 million and ~~$170~~$95 million under the commercial paper facility at ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, respectively. The Company also has a $700 million multi-currency revolving credit facility which serves as a back-stop credit facility for the Company's commercial paper program. At ~~September 30, 2022~~March 31, 2023 and December 31, ~~2021,~~2022, there were no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $48 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings of $21 million. At ~~September 30, 2022,~~March 31, 2023, the weighted-average interest rate for short-term debt was ~~4.0%~~5.4%.

The Company’s revolving credit facility, term loans and senior notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. At ~~September 30, 2022,~~March 31, 2023, the Company was in compliance with all debt covenants.As a result of the Company’s failure to file its unaudited financial statements for the fiscal quarters ended March 31, 2022 and June 30, 2022 by the reporting deadlines, the Company obtained the consents of the requisite lenders and noteholders of its outstanding indebtedness to extend the time period for delivery of such unaudited financial statements until November 14, 2022. Those financial statements were delivered on November 9, 2022 and therefore, the Company has not suffered an event of default as a result of the delayed filings.

3527

NOTE 1413 – GOODWILL AND INTANGIBLE ASSETS

The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually as of April 1 or more frequently if events or changes in circumstances indicate the asset might be impaired.

In ~~preparing its financial statements for~~ the ~~quarter ended September 30,~~third and fourth quarters of 2022, the Company identified indicators of a "more likely than not" impairment related to its Digital Dental Group and Equipment & Instruments reporting units included within the Technologies & Equipment segment. The Company has experienced adverse macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and ~~increased raw material, supply chain and service costs,~~certain indefinite-lived intangible assets, which ~~are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows.~~

~~The fair values of the two reporting units above were computed using a discounted cash flow model with inputs developed using both internal and market-based data. The Company's significant assumptions~~resulted in the discounted cash flow model included, but were not limited to, the weighted average cost of capital, revenue growth rates (including perpetual growth rates), and operating margin percentages of the reporting unit's business. As a result, the Company recorded a pre-tax goodwill impairment ~~charge related to the Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment of $1,100 million and $87 million, respectively.~~

The timing of this impairment charge in the third quarter was the result of current macroeconomic conditions, including the rising interest rate environment and broad declines in equity valuations. Since the second quarter, core underlying market interest rates, which serve as the basis for the discount rate assumptions in our impairment models, rose by approximately 200 basis points. Further, earnings forecasts were reduced for several reporting units as these forecasts were impacted by ongoing macroeconomic forces. Global demand has weakened for certain products in the third quarter as inflationary pressures impacted the discretionary spending behavior of our customers, which has introduced new competitive challenges. Additionally, raw materials, supply chain, and service costs have all increased due to changes in our business model and broad inflationary trends.

charges. At ~~September 30, 2022,~~March 31, 2023, the remaining goodwill related to the Digital Dental Group and Equipment & Instruments reporting units was ~~$234~~$235 million and ~~$192~~$193 million, respectively. As the fair value of these reporting units approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. Based on quantitative analysis performed for the other three reporting units within the Technologies & Equipmentrespectively, and ~~Consumables segments, the Company believes there is no indication that~~ the carrying value ~~"more likely than not" exceeds the fair value in each case as~~ of ~~September 30, 2022; however, any further deterioration in key assumptions could result in impairment charges in the future.~~

For the Company's reporting units that were not impaired, the Company applied a hypothetical sensitivity analysis by increasing the discount rate of these reporting units by 100 basis points and, in a separate test, reducing by 10% the fair value of those reporting units. If discount rates were hypothetically increased by 100 basis points at September 30, 2022, one reporting unit within the Technologies & Equipment segment would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was $1,068 million at September 30, 2022.

In preparing the financial statements for the quarter ended September 30, 2022, in conjunction with the goodwill impairment, the Company tested the intangible assets related to the businesses within the Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment for impairment. The Company also identified an indicator of impairment for indefinite-lived intangible assets within the Consumables reporting unit within the Consumables segment. Intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method, or using a qualitative assessment. The Company's significant assumptionswith impairments in the relief from royalty method included, but were not limited to, revenue growth rates (including perpetual growth rates), royalty rates, and discount rates. As a result, the Company recorded an impairment chargethird or fourth quarters of ~~$66~~2022 was $157 million, ~~$26~~$15 million, and $2$40 million for the Digital Dental Group, Equipment & Instruments, and Consumables reporting units, respectively, for its indefinite-lived intangible assets for the three months ended September 30, 2022. The impairment charge was primarily driven by macroeconomic factors such as higher cost of capital, cost inflation, unfavorable foreign currency impacts, and increased supply chain costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows. This charge was recorded in Intangible asset impairment and other costs in the Consolidated Statements of Operations.respectively. As the fair value of these reporting units and indefinite-lived intangible assets continues to approximate carrying ~~value~~values as of ~~September 30, 2022,~~March 31, 2023, any further decline in key assumptions could result in additional ~~impairment~~impairments in future periods. ~~Based on~~Refer to Note 12 - Goodwill and Intangible Assets within the 2022 Form 10-K for further information regarding prior year impairment.

For the three months ended March 31, 2023, the Company considered qualitative ~~assessments performed on~~and quantitative factors to determine whether any events or changes in circumstances had resulted in the likelihood that the goodwill or indefinite-lived intangible assets ~~related to~~may have become more likely than not impaired during the ~~businesses~~course of the quarter, and concluded there were no such indicators. The Company performed a hypothetical sensitivity analysis by increasing the discount rate by 100 basis points and, in a separate test, reducing 10% the ~~two other~~fair value of the reporting units and indefinite-lived intangible assets. Under this sensitivity, one additional reporting unit within the Technologies & Equipment segment the Company believes there is no indication that the carrying value "more likely than not" exceeds the fair value of these intangible assets in each case as of September 30, 2022; however, any further deterioration in key assumptions could result in impairment charges in the future.

For the Company’s indefinite-lived intangible assets that were not impaired, the Company applied a hypothetical sensitivity analysis. If the fair value of each of these indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 100 basis points as of September 30, 2022, the fair value ofand certain indefinite-lived intangible assets within the Technologies & Equipment and Consumables segments would be less than book value and are considered at-risk based on the sensitivity analysis. The carrying value of these indefinite-lived intangibles within the Technologies & Equipment segment would have a fair value less than 10% in excess of book value. Goodwill associated with this reporting unit was $1,134 million at March 31, 2023, and ~~Consumables segments~~the carrying value of these indefinite-lived intangible assets was ~~$43~~$57 million ~~and $30 million, respectively,~~ at ~~September 30, 2022.~~March 31, 2023.

Any deviation in actual financial results compared to the forecasted financial results or valuation assumptions used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings.

A reconciliation of changes in the Company’s goodwill by reportable segment were as follows:


(in millions)	(in millions)	Technologies & Equipment		Consumables		Total		(in millions)	Technologies & Equipment		Consumables		Total

Balance at December 31, 2021
Balance at December 31, 2022								Balance at December 31, 2022
Goodwill	Goodwill	$	5,989	$	880	$	6,869	Goodwill	$	5,902	$	866	$	6,768
Accumulated impairment losses	Accumulated impairment losses	(2,893)		—		(2,893)		Accumulated impairment losses	(4,080)		—		(4,080)
Goodwill, net	Goodwill, net	$	3,096	$	880	$	3,976	Goodwill, net	$	1,822	$	866	$	2,688

Impairment		(1,187)		—		(1,187)
Translation and other		(170)		(35)		(205)

Balance at September 30, 2022
Translation								Translation	9		4		13

Balance at March 31, 2023								Balance at March 31, 2023
Goodwill	Goodwill	$	5,819	$	845	$	6,664	Goodwill	$	5,911	$	870	$	6,781
Accumulated impairment losses	Accumulated impairment losses	(4,080)		—		(4,080)		Accumulated impairment losses	(4,080)		—		(4,080)
Goodwill, net	Goodwill, net	$	1,739	$	845	$	2,584	Goodwill, net	$	1,831	$	870	$	2,701

3728

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


		September 30, 2022						December 31, 2021							March 31, 2023						December 31, 2022
(in millions)	(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	Developed technology and patents	$	1,569	$	(764)	$	805	$	1,729	$	(762)	$	967	Developed technology and patents	$	1,671	$	(888)	$	783	$	1,658	$	(848)	$	810
Tradenames and trademarks	Tradenames and trademarks	269		(90)		179		269		(79)		190		Tradenames and trademarks	274		(99)		175		273		(96)		177
Licensing agreements	Licensing agreements	31		(26)		5		36		(32)		4		Licensing agreements	30		(26)		4		30		(26)		4
Customer relationships	Customer relationships	1,005		(553)		452		1,091		(545)		546		Customer relationships	1,061		(620)		441		1,057		(600)		457
Total definite-lived	Total definite-lived	$	2,874	$	(1,433)	$	1,441	$	3,125	$	(1,418)	$	1,707	Total definite-lived	$	3,036	$	(1,633)	$	1,403	$	3,018	$	(1,570)	$	1,448

Indefinite-lived tradenames and trademarks	Indefinite-lived tradenames and trademarks	$	426	$	—	$	426	$	598	$	—	$	598	Indefinite-lived tradenames and trademarks	$	454	$	—	$	454	$	450	$	—	$	450
In-process R&D (a)	In-process R&D (a)	8		—		8		14		—		14		In-process R&D (a)	5		—		5		5		—		5
Total indefinite-lived	Total indefinite-lived	$	434	$	—	$	434	$	612	$	—	$	612	Total indefinite-lived	$	459	$	—	$	459	$	455	$	—	$	455

Total identifiable intangible assets	Total identifiable intangible assets	$	3,308	$	(1,433)	$	1,875	$	3,737	$	(1,418)	$	2,319	Total identifiable intangible assets	$	3,495	$	(1,633)	$	1,862	$	3,473	$	(1,570)	$	1,903

(a) Intangible assets acquired in a business combination that are in-process and used in research and development ("R&D") activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed. ~~During the third quarter of 2022, the completion of certain R&D activities occurred, resulting in the reclassification of $5 million of in-process R&D to in-service assets with a definite life.~~

During the second quarter of 2021, the Company purchased certain developed technology rights for an initial payment of $3 million. The purchase consideration also includes minimum guaranteed contingent payments of $17 million to be made upon reaching certain regulatory and commercial milestones. The contingent payments are not yet considered probable of payment as of ~~September 30, 2022.~~

March 31, 2023.

3829

NOTE 1514 – COMMITMENTS AND CONTINGENCIES

Contingencies

On January 25, 2018, Futuredontics, Inc., a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Calethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato). The court in Cato approved the settlement in that case, the settlement payment has been made, and the court dismissed the lawsuit. The parties tohave also reached a settlement in the Olivares and Holt ~~are in the process of seeking court approval of that settlement. The expected settlement amount,~~class action, which is immaterial to the financial statements of the Company. The final settlement amount has been ~~recorded as an accrued liability within~~approved by the ~~Company's consolidated balance sheet as~~Court and was paid by the Company in the first quarter of ~~September 30, 2022.~~2023.

On June 7, 2018, and August 9, 2018, two putative class action suits were filed, and later consolidated, in the Supreme Court of the State of New York, County of New York claiming that the Company and certain individual defendants, violated U.S. securities laws (the "State Court Action") by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. ("Sirona") with DENTSPLY International Inc. (the "Merger"). The amended complaint alleges that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company's products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company's stock in the Merger. On September 26, 2019, the Court granted the Company's motion to dismiss all claims and a ~~judgement~~judgment dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs' ~~post-judgement~~post-judgment motion to vacate or modify the ~~judgement~~judgment and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the ~~post-judgement~~post-judgment motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court's decision dismissing the action. The plaintiffs' appeals and the Company's cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision.

On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants (the "Federal Class Action"). The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company's stock during the period February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, ~~2021. Briefing~~2021, with briefing on the motion ~~to dismiss was~~ fully submitted on May 21, ~~2021,~~2021. The Company’s motion to dismiss was denied in a ruling by the Court on March 29, 2023 and, ~~that motion~~therefore, the Company’s answer to the second amended complaint is ~~currently pending before the Court.~~due on May 12, 2023.

On June 2, 2022, the Company was named as a defendant in a putative class action filed in the ~~United States~~U.S. District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371 (S.D. Ohio), and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the ~~United States~~U.S. District Court for the Southern District of New York captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period from June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated ~~United States~~U.S. securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognizes revenue tied to distributor rebate and incentive programs. On March 27, 2023, the Court in the Southern District of Ohio ordered the transfer of the putative class action to the Southern District of New York.

39On March 21, 2023, Mr. Carlo Gobbetti filed a claim in the Milan Chamber of Arbitration against Dentsply Sirona Italia S.r.l., Italy, a wholly owned subsidiary of the Company, seeking a total of €28 million for the alleged failure to pay a portion of the purchase price pursuant to a Share Purchase Agreement, dated October 8, 2012 (the “SPA”), in which Sirona Dental Systems, S.r.l., which at the time of execution of the SPA was a wholly-owned subsidiary of Sirona Dental Systems, Inc., acquired all of the shares of MHT S.p.A., an Italian corporation, from Mr. Gobbetti, and various other sellers. Sirona Dental Systems S.r.l. merged into Dentsply Italia S.r.l. in 2018 (the surviving entity is now Dentsply Sirona Italia S.r.l.). In connection with the closing of that transaction, SIRONA Dental Systems GmbH paid an amount equal to €7 million into an escrow account (the “Escrow Account”). The proceeds of the Escrow Account were to be released to Mr. Gobbetti and the other sellers upon the satisfaction of certain conditions, including the delivery by July 2013 of a new prototype of an MHT S.p.A. camera which had to meet certain specifications. Mr. Gobbetti claims that he is entitled to receive the €7 million outstanding balance of the purchase price under the SPA, plus €21 million for damages incurred as a consequence of the failure to make the payment. Mr. Gobbetti claims that he has a right to receive the full purchase price under the SPA even if the conditions set out in the SPA to deliver a prototype of the MHT S.p.A. camera by July 2013 were not met. Dentsply Sirona Italia S.r.l. denies that Mr. Gobbetti and the other sellers were entitled to receive the funds deposited in the Escrow Account. Dentsply Sirona Italia S.r.l.’s initial response, including preliminary objections, is due by May 15, 2023. Dentsply Sirona Italia S.r.l. denies it has liability in this matter and intends to vigorously defend against Mr. Gobbetti’s claims.

NoExcept as noted above, no specific amounts of damages have been alleged in these lawsuits. WeThe Company will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. ~~We intend~~The Company intends to defend these lawsuits vigorously, but there can be no assurance that wethe Company will be successful in any defense. If any of the lawsuits are decided adversely, wethe Company may be liable for significant damages directly or under our indemnification obligations, which could adversely affect our business, results of operations and cash flows. At this stage, wethe Company is are unable to assess whether any material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.

~~As a result~~The Internal Revenue Service (“IRS”) conducted an examination of ~~an audit by~~ the ~~IRS~~U.S. federal income tax returns for ~~fiscal~~tax years 2012 through ~~2013, on~~2013. In February ~~11,~~ 2019, the IRS issued to the Company a “30-day letter” and a Revenue Agent’s Report (“RAR”), relating to the Company’s worthless stock deduction in 2013 in the amount of $546 million. The RAR disallows the deduction and, after adjusting the Company’s net operating loss carryforward, asserts that the Company is entitled to a refund of $5 million for 2012, has no tax liability for 2013, and owes a deficiency of $17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company’s 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Appeals Office Team onin October ~~28,~~ 2020, and onin November ~~13,~~ 2020 submitted a supplemental response to questions raised by the Appeals Team. ~~The Company’s position continues to be reviewed by~~During the ~~IRS Appeals Office team. The Company believes the IRS' position is without merit and believes that it is more likely-than-not the Company’s position will be sustained upon further~~first quarter of 2023, after an extended review by the IRS Appeals Office ~~Team. The~~team, the Company ~~has not accrued~~received a ~~liability relating~~notice from the IRS, allowing the Company’s worthless stock deduction for tax year 2013. As a result, the Company is anticipating a refund of $5 million for tax year 2012 with no further adjustments to the 2013 tax return.

IRS is conducting an examination of our U.S. federal income tax returns for the tax years 2015 through 2016. In April 2023, the Company received a Notice of Proposed Adjustment (“NOPA”) from the IRS examination team proposing an adjustment related to an internal reorganization completed in 2016 with respect to the integration of certain operations of Sirona Dental Systems, Inc. following its acquisition in 2016. Although the proposed adjustment does not result in any additional federal income tax ~~adjustments.~~liability for the internal reorganization, if sustained, the proposed adjustment would result in the company owing additional federal income taxes on a distribution of $451 million as a result of a stock redemption that occurred after the internal reorganization was completed in 2016. We believe that we accurately reported the federal income tax consequences of the internal restructuring and stock redemption in our tax returns and will submit an administrative protest with the IRS Independent Office of Appeals contesting the examination team’s proposed adjustments if the issue is not resolved with the IRS examination team. We intend to vigorously defend our reported positions and believe that it is more likely-than-not that our position will be sustained. However, the outcome of this dispute involves a number of uncertainties, including ~~those inherent in the valuation of various assets at the time of the worthless stock deduction, and~~ those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute ~~would result in a current period charge to earnings and~~ could have a material adverse effect inon the consolidated results of operations, financial position, and liquidity of the Company.

The Swedish Tax Agency has disallowed certain of the Company’s interest expense deductions for the tax years from 2013 to 2018. If such interest expense deductions were disallowed, the Company would be subject to an additional $36 million in tax expense. The Company has appealed the disallowance to the Swedish Administrative Court. With respect to such deductions taken in the tax years from 2013 to 2014, the Court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish Administrative Court. On November 5, 2018, the Company delivered its final argument to the Administrative Court of Appeals at a hearing. The European Union Commission has taken the view that Sweden’s interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. This view has now been confirmed by the European Union Court of Justice in a preliminary ruling requested by the Swedish Supreme Administrative Court. Subsequently, the Swedish Tax Authority has conceded in pending court proceedings that the Company should be granted further interest expense deductions, but still claims that interest expense deductions incurring a maximum additional tax expense of $7 million should be disallowed on grounds not relating to European Union law.

The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the ~~above-described~~above described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity.

While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

Commitments

Purchase Commitments

The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At ~~September 30, 2022,~~March 31, 2023, non-cancelable purchase commitments are as follows:


(in millions)	(in millions)			(in millions)

2022		$	66

2023	2023	175		2023	$	158
2024	2024	77		2024	148
2025	2025	58		2025	59
2026	2026	69		2026	55
2027				2027	6
Thereafter	Thereafter	—		Thereafter	3
Total	Total	$	445	Total	$	429

The above information should be read in conjunction with Part II, Item 7 “Contractual Obligations” and Part II, Item 8, Note 22 “Commitments and Contingencies” in our ~~2021~~2022 Form ~~10-K/A.~~10-K.

Off-Balance Sheet Arrangements

As of ~~September 30, 2022,~~March 31, 2023, we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above.

Indemnification

In the normal course of business to facilitate sale of our products and services, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.

It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material effect on our results of operations, cash flows or financial position. As of ~~September 30, 2022,~~March 31, 2023, we did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period.

4133

NOTE 15 – SUBSEQUENT EVENTS

In conjunction with the restructuring plan announced in February, the Company made certain changes in the reporting structure for its global business units effective April 1, 2023 which will result in a change in reportable segments beginning in the second quarter of 2023. The new structure will consist of four reportable segments:

•Connected Technology Solutions, consisting of the Company's equipment, instruments and CAD/CAM businesses;

•Essential Dental Solutions, consisting of the Company's endodontic, restorative and preventive consumables business;

•Implant & Orthodontic Solutions, consisting of the Company's implant systems and aligner solutions; and

•Wellspect Healthcare, consisting of the Company's urology catheters and other healthcare-related consumable business.

DENTSPLY SIRONA Inc. and Subsidiaries

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

Information included in or incorporated by reference in this Form 10-Q, and other filings with the SEC and the Company’s press releases or other public statements, contains or may contain forward-looking statements. Please refer to the discussion under the header “Forward-Looking Statements and Associated Risks” in the forepart of this Form 10-Q.

Company Profile

DENTSPLY SIRONA Inc. is ~~a leading~~the world's largest manufacturer of professional dental products and technologies, with a ~~135-year~~136-year history of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions ~~for~~offering including dental equipment and dental consumable products under a strong portfolio of world class brands. The Company also manufactures and markets healthcare consumable products. Dentsply Sirona’s products provide innovative, high-quality, and effective solutions to advance patient care and deliver better, safer, and faster dentistry. Dentsply Sirona’s worldwide headquarters is located in Charlotte, North Carolina. The Company’s shares of common stock are listed in the United States on the Nasdaq stock market under the symbol XRAY.

Material Weaknesses in Internal Control Over Financial Reporting Identified During the ~~Recent~~Prior Year Investigation

As ~~first~~previously disclosed, in the Company's Form 12b-25 filed on May 10, 2022, the Audit and Finance Committee of the Company's Board of Directors (the "Audit and Finance Committee"), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company ("the North America Investigation"). In the North America Investigation, the Audit and Finance Committee concluded thatmanagement determined there was no evidence of intentional wrongdoing or fraud but determined that certain former members of senior management, including the Company's former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company's Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. While the North America Investigation was ongoing, the Audit and Finance Committee determined that the scope of the internal investigation should be expanded to analyze an increase in returns of products in China during the fourth quarter of 2021 previously identified by management (the "China Investigation"). Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company's local commercial team in China, as well as the head of the Company's Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company's local accounting organization, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company's local commercial team in China, as well as the former Chief Financial Officer and the head of the Company's Asia-Pacific commercial organization violated the Company's Code of Ethics and Business Conduct.

~~Refer to the Explanatory Note to the 2021 Form 10-K/A for more information on each of these investigations and the related findings of the Audit and Finance Committee.~~

In connection with the restatement of the financial statements and related disclosures for the three and nine months ended September 30, 2021 and for the fiscal year ended December 31, 2021, management re-evaluated the effectiveness of the Company’s internal control over financial reporting and identifiedwere material weaknesses in the Company’s internal control over financial reporting as of ~~September 30, 2021. These material weaknesses in internal controls over financial reporting were~~December 31, 2021, which have not been remediated as of ~~September 30, 2022 and~~ ~~are not remediated through the date of this filing.~~March 31, 2023. For more information about the ~~internal investigation and its findings, the specific~~identified material weaknesses in internal control over financial reporting and the ~~current status of the~~ Company’s remedial actions, please see Part ~~II,~~I, Item 9A4 Controls and Procedures of ~~the 2021~~this Form ~~10-K/A.~~10-Q.

BUSINESS

The Company operates in two operating segments, Technologies & Equipment ("T&E") and Consumables.

The T&E segment is responsible for the design, manufacture, sales and ~~sale~~distribution of products including dental implants, CAD/CAM systems, orthodontic ~~clear~~ aligner products, imaging systems, treatment centers and instruments, as well as certain healthcare device products, primarily catheters.

The Consumables segment is responsible for the design, manufacture, sales and ~~sale~~distribution of dental consumable products ~~within the product~~which include categories of preventive, restorative, endodontic, and dental laboratory application.

~~Impact~~The impacts of COVID-19

The Company's financial results and operations continue to be ~~impacted~~affected by the COVID-19 pandemic and ~~its effect~~the pressure it has placed on inflation, supply chains, distribution networks and consumer behavior. Information pertaining to the impact of the pandemic on the Company's business during 2021 as well as the Company's response can be found in “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2021 Form 10-K/A. Updates to that summary of impactKey impacts for the ~~nine~~three months ended ~~September 30, 2022~~March 31, 2023 are as follows:

•As further described in the "Results of Operations" discussion below, ~~the Company continues~~we continue to experience supply chain challenges partly resulting from the pandemic including increased lead times, limited availability of certain components, raw material price increases, and higher procurement and shipping costs. ~~As a result of supply chain constraints, the Company continued~~We are continuing to have an elevated backlog at September 30, 2022 relative to historical levels, primarily in connection with orders on hand for imaging equipment which we are unable to fill due to continued shortages of electronic components. The Company has continued takingtake steps to mitigate the impact of these trends, including seeking alternative supplier sources for key raw materials.

•Sales continue to be impacted in certain geographic ~~area~~sareas by public response to the COVID-19 pandemic. Towards the end of the first quarter of 2022, authorities in China ~~began~~started to periodically re-impose severe restrictions on individual and business activities in response to the resurgence of COVID-19 infections from variants of the virus, resulting in a loss of sales due to distribution constraints and lower demand from reduced patient traffic locally. ~~Primarily~~Although these restrictions in China have been substantially lifted as of the end of the first quarter of 2023, a ~~result~~slow return of patient traffic to previous levels has continued to affect results in China. Partly due to these factors, sales ~~in China~~ declined by ~~$55~~$14 million induring the first ~~nine months~~quarter of ~~2022 compared~~2023 relative to the first ~~nine months~~quarter of ~~2021.~~2022. Adverse trends in ~~certain~~China or other regions could persist if these ~~restriction~~srestrictions are renewed as a result of additional outbreaks. While most government authorities have not re-imposed restrictions with significant impacts, it ~~continues to be unclear when the remaining constraints will be lifted, and~~remains uncertain to what degree future variants of the virus or renewed restrictions ~~in other markets~~ may impact ~~short-term~~ demand for ~~the Company's~~our products more broadly.

~~Impact~~

The impact of ~~Russia’s Invasion of~~developments in Ukraine

OnIn February ~~24,~~ 2022, ~~Russian forces launched military action against Ukraine, resulting in warfare and significant disruption in the region ("the conflict"). As~~as a result of the invasion of Ukraine by Russia, economic sanctions ~~have been~~were imposed by the U.S., the ~~European Union,~~EU, and certain other countries on ~~certain~~ Russian financial institutions ~~businesses~~ and ~~individuals.~~

~~The Company does not have significant operations in Russia or Ukrain~~e. The Company’s net sales in Russia and Ukraine approximate 3% of the Company’s consolidated net sales, and the Company’s net assets in these two countries aggregate to $90 million, or less than 2% of consolidated net assets. These net assets include $73 million of cash and cash equivalents held within Russia as of September 30, 2022.businesses. Due to the medical nature of ~~its~~our products, the current sanctions have not materially restricted the Company's ability to continue selling many of our products to customers located in Russia. The Company also sources certain raw materials and components from Russia and Ukraine, and to minimize thethe adverse impacts from disrupted supply chains related to these items, itthe Company has purchased sufficient quantities for the near term, and isare in the process of identifying ~~alternate~~alternative sources for the longer term. The Company’s operations in Ukraine consist primarily of ~~research and development~~R&D activities, which continue uninterrupted from other locations in order to focus on the safety of employees. Overall, the Company's operations in Russia and Ukraine have not been materially impacted by the conflict, and consequently, the Company has not recorded any allowance for doubtful accounts, inventory reserves, or asset impairments during the ~~nine months~~quarter ended ~~September 30, 2022~~March 31, 2023 as a result of these developments.

For the quarter ended March 31, 2023, net sales in Russia and Ukraine were approximately 3% of our consolidated net sales, and net assets in these countries were $76 million. These net assets include $57 million of cash and cash equivalents held within Russia as of March 31, 2023. Due to currency control measures imposed by the Russian government which include restrictions on the ability of companies to repatriate or otherwise remit cash from their Russian-based operations to locations outside of Russia, we may be limited in our ability to transfer this cash balance out of Russia without incurring substantial costs, if at all.

While neither Russia nor Ukraine constitutes a material portion of our business, a significant escalation or expansion of economic disruption or the conflict's current scope could result in a loss of sales, disrupt our supply chain, broaden inflationary costs, and have a material adverse effect on our results of operations. ~~For additional discussion~~

The impact of ~~associated risks, refer~~global economic conditions

In addition to ~~Part I, Item 1A, "Risk Factors”~~the residual impacts of the ~~2021 Form 10-K/A.~~COVID-19 pandemic and the war in Ukraine, markets in several regions, particularly in Europe, have experienced varying degrees of recessionary pressures and face continued concerns about the systemic impacts of adverse economic conditions and geopolitical issues. In addition, changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, and the conflict in Ukraine have all contributed to a period of higher inflation across the industry and the regions in which the Company operates.

As a result, the Company has experienced higher prices for certain of our raw materials, particularly for electronic components which have in some cases required incremental procurement costs such as brokers' fees during the year, and a consequently negative impact to margins. The Company has also experienced delays in converting our backlog due to continued supply chain disruptions, which has negatively impacted both revenues and margins. Although the Company has experienced recent improvement in its supply chain, we expect a continuation of these trends including disruptions and inflationary pressure on the cost of both raw material and wages, the effect of which will depend on the Company’s ability to successfully mitigate and offset the related impacts.

The deterioration in macroeconomic conditions has also negatively affected demand for the Company's products and may continue to do so into the future. Specifically, the increase in interest rates in the last twelve months has put pressure on the ability of our customers to obtain financing for equipment purchases which affects volumes for these products. Additionally, the recessionary environment in general particularly for certain regions such as southern Europe has depressed demand for elective procedures including sales of implants and aligner solutions.

In anticipation of a continued inflationary trend and potentially deteriorating macroeconomic environment, the Company has attempted to mitigate these pressures through the following actions, among others:

•Driving strategic procurement initiatives to leverage alternative sources of raw materials and transportation;

•Implementing cost-containment measures, as well as intensifying continuous improvement and restructuring programs, in our manufacturing and distribution facilities and other areas of our business; and

•Optimizing our customer management and implementing strategic investments in our commercial sales organization in key markets, particularly the U.S.

4336

As explained further in the Results of Operations section below, the Company has partly offset these elevated costs in certain areas of the business with price increases during the year. Should the higher inflationary environment continue, the Company may be likely to continue to be unable to raise the prices of our products and services sufficiently to keep up with the rate of inflation which could have a material adverse effect on our results of operations and financial condition.

RESULTS OF OPERATIONS, THREE MONTHS ENDED ~~SEPTEMBER 30, 2022~~MARCH 31, 2023 COMPARED TO THREE MONTHS ENDED ~~SEPTEMBER 30, 2021~~MARCH 31, 2022

Net Sales

The Company presents net sales comparing the current year periods to the prior year periods. In addition, the Company also presents the changes in net sales on an organic sales basis, which is a Non-GAAP measure. The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired and divested businesses recorded prior to the first anniversary of the acquisition or divestiture; (2) net sales attributable to ~~disposed businesses or~~ discontinued product lines in both the current and prior year ~~periods,~~periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior ~~period's foreign~~period’s currency exchange rates.

~~Organic sales~~The "organic sales" measure is not calculated in accordance with US GAAP; therefore, this item represents a Non-GAAP measure. This Non-GAAP measure may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. Organic sales is an important internal measure for the Company, ~~which is utilized regularly by~~and its senior management ~~in the review~~who receive a monthly analysis of operating ~~results. Organic~~results that includes organic sales. The performance of the Company is measured on this metric along with other performance metrics.

The Company discloses changes in organic sales ~~is disclosed~~ to allow investors to evaluate the performance of the Company’s operations exclusive of ~~certain~~the items listed above that impact the comparability of results from period to period and may not be indicative of past or future performance of the normal operations of the Company. The Company believes that this supplemental information is helpful in understanding underlying net sales trends.

The Company's net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, and ~~2021, and~~a reconciliation to the ~~reconciliation to~~percentage change in organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	947	$	1,040	$	(93)	(8.9	%)	Net sales	$	978	$	969	$	9	0.9	%
Foreign exchange impact	Foreign exchange impact							(8.2	%)	Foreign exchange impact							(4.2	%)

Organic sales	Organic sales							(0.7	%)	Organic sales							5.1	%

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

~~Organic~~The increase in organic sales ~~declined~~was primarily due to ~~the continued impact of supply chain constraints affecting the ability to fulfill orders~~strong demand for ~~certain Equipment & Instruments~~Consumables and ~~Consumables~~Orthodontic products, ~~and weaker performance~~particularly in the United States, ~~partly due to~~as well as a benefit from price increases implemented in the ~~timing~~prior year. This increase was offset by overall weaker demand for Implants. Sales in the Rest of ~~sales to distributors as explained below, and the impact of COVID-19 variants on~~World region were also negatively impacted by reduced demand from patient traffic in ~~China. These drivers were mostly offset by strong performance in volumes for Orthodontics products.~~certain markets, particularly, China as a result of COVID-19 variants and related restrictions.

Net Sales by Segment

Technologies & Equipment

Net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and reconciliation of net sales to organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	556	$	612	$	(56)	(9.0	%)	Net sales	$	548	$	565	$	(17)	(3.0	%)
Foreign exchange impact	Foreign exchange impact							(9.6	%)	Foreign exchange impact							(4.7	%)

Organic sales	Organic sales							0.6	%	Organic sales							1.7	%

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

The ~~slight~~ increase in organic sales was primarily due to higher volumes for Orthodontics products, as well as an overall benefit from sales of new products and price increases. ~~These increases were mostly offset by a decline in sales~~Sales of CAD/CAM products in the United States ~~relative to the comparable quarter of 2021,~~also increased due in part to the timing of sales to distributors as explained below. ~~Sales have also continued to be adversely impacted~~These increases were partly offset by ~~supply chain constraints~~lower demand for Implants products in all regions and ~~reduction in volumes due to product availability, particularly for certain~~ Equipment & Instruments products ~~which rely on electronic components.~~in the United States and Europe.

Consumables

Net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and reconciliation of net sales to organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	391	$	428	$	(37)	(8.7	%)	Net sales	$	430	$	404	$	26	6.4	%
Foreign exchange impact	Foreign exchange impact							(6.2	%)	Foreign exchange impact							(3.4	%)

Organic sales	Organic sales							(2.5	%)	Organic sales							9.8	%

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

The ~~decrease~~increase in organic sales was primarily driven by ~~lower~~higher sales volumes for Endodontic & Restorative products, particularly in the United States and ~~China, offset by~~Europe due to strong retail demand, as well as a benefit from price increases ~~and demand for new products.~~made in the prior year.

Net Sales by Region

United States

Net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and reconciliation of net sales to organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	357	$	384	$	(27)	(7.2	%)	Net sales	$	351	$	308	$	43	13.9	%
Foreign exchange impact	Foreign exchange impact							(2.0	%)	Foreign exchange impact							(0.7	%)

Organic sales	Organic sales							(5.2	%)	Organic sales							14.6	%

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

The ~~decrease~~increase in organic sales was driven primarily by ~~soft~~strong demand for Consumables ~~products,~~ and ~~lower~~Orthodontics products. Sales also benefited from higher wholesale volumes for CAD/CAM products relative to prior ~~year.~~year due in part to timing of sales to distributors. Volumes for CAD/CAM products in the ~~third~~comparable first quarter of ~~2021 benefited from~~2022 were negatively affected by a ~~build~~reduction in distributor inventory of approximately ~~$35~~$10 million, partly as a result of incremental incentives offered ~~during that period which did not recur in 2022,~~at the end of 2021. This reduction is compared to a distributor inventory build of approximately $10 million during the ~~third~~first quarter of ~~2022 as orders from distributors have weakened~~2023, which the Company notes represents a normal seasonal trend in ~~response to a slowdown in retail demand. Sales volumes during the three months ended September 30, 2022,~~dealer inventory levels. These increases were ~~also negatively impacted~~partially offset by ~~ongoing global supply chain constraints and reduction~~declines in volumes ~~due to product availability, particularly~~ for certain Equipment & Instruments products. Sales of certain of these products which rely on electronic ~~components. The decline in sales volume was partly offset~~components continue to be affected by ~~overall growth in the Orthodontics business.~~supplier shortages.

Europe

Net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and reconciliation of net sales to organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	358	$	393	$	(35)	(8.8	%)	Net sales	$	396	$	411	$	(15)	(3.6	%)
Foreign exchange impact	Foreign exchange impact							(11.8	%)	Foreign exchange impact							(4.7	%)

Organic sales	Organic sales							3.0	%	Organic sales							1.1	%

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

The increase in organic sales was primarily due to overall higher volumes for ~~Equipment & Instruments, Orthodontics, and~~ Endodontic & Restorative products as a result of favorable market trends, ~~and demand,~~ as well as a benefit from prior year price increases. ~~The organic sales~~Sales growth was partly offset by ~~ongoing global supply chain constraints, and reduction~~reductions in volumes ~~due to product availability, particularly~~ for certain Equipment & Instruments products ~~which rely on electronic components.~~and Implants.

Rest of World

Net sales for the three months ended ~~September 30,~~March 31, 2023 and 2022, ~~and 2021,~~ and reconciliation of net sales to organic sales is as follows:


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022		2021		$ Change		% Change		(in millions, except percentages)	2023		2022		$ Change		% Change

Net sales	Net sales	$	232	$	263	$	(31)	(11.6	%)	Net sales	$	231	$	250	$	(19)	(7.6	%)
Foreign exchange impact	Foreign exchange impact							(11.7	%)	Foreign exchange impact							(7.5	%)

Organic sales	Organic sales							0.1	%	Organic sales							(0.1	%)

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

Organic sales were flat as higher sales for ~~Other Consumables and~~ Equipment & Instruments and Consumables products were offset by declines for ~~Endodontic & Restorative~~Implants and ~~Implants~~ CAD/CAM products. In the first quarter of 2023, the Company continued to be impacted by the anticipated local volume-based procurement program in China resulting in price reductions for Implant products. Volumes during the period overall were also negatively impacted by ongoing global supply chain constraints and the adverse impact of COVID-19, particularly in China which was affected by lower demand resulting from ongoing government restrictions affecting patient traffic. In the third quarter of 2022, the Company began to see softer demand for Implants products in China ahead of the local volume based procurement program taking effect. Although sales have not yet been materially impacted, the Company expects sales of our Implants products in China will be negatively affected by price reductions as a result of this program which is anticipated to take effect beginning late in the fourth quarter of 2022 or the first quarter of 2023.China.

Gross Profit


		Three Months Ended September 30,											Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022			2021			$ Change		% Change		(in millions, except percentages)	2023			2022			$ Change		% Change

Gross profit	Gross profit	$	508		$	569		$	(61)	(10.7	%)	Gross profit	$	519		$	521		$	(2)	(0.4	%)

Gross profit as a percentage of net sales	Gross profit as a percentage of net sales	53.7		%	54.7		%	(100) bps				Gross profit as a percentage of net sales	53.1		%	53.8		%	(70) bps

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

Gross profit for the quarter was ~~negatively impacted by~~flat as the ~~decrease in volumes as~~sales volume increases described above ~~as well as~~were offset by foreign currency translation headwinds of ~~$50~~$26 million. Gross profit margins as a percentage of net sales declined due to ~~the impact of higher raw materials, labor,~~these foreign currency headwinds and increased inflationary pressures on material and distribution ~~costs as a result of supply chain constraints and global inflation during the period, as well as the impact of unfavorable product mix.~~costs. These ~~decreases~~factors were ~~partly~~mostly offset by ~~the benefit of~~ price increases from the prior year, favorability in mix driven by higher demand for higher margin Consumables products, and ~~favorable foreign currency transaction gains.~~improvements in the profitability of Orthodontics products.

4639

Operating Expenses


		Three Months Ended September 30,											Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022			2021			$ Change		% Change		(in millions, except percentages)	2023			2022			$ Change		% Change

Selling, general and administrative expenses ("SG&A")	Selling, general and administrative expenses ("SG&A")	$	401		$	395		$	6	1.9	%	Selling, general and administrative expenses ("SG&A")	$	416		$	376		$	40	10.7	%
Research and development expenses ("R&D")	Research and development expenses ("R&D")	41			39			2		5.2	%	Research and development expenses ("R&D")	46			45			1		3.2	%
Goodwill impairment		1,187			—			1,187		NM
Intangible asset impairment and other costs		97			3			94		NM

Restructuring and other costs												Restructuring and other costs	59			3			56		NM

SG&A as a percentage of net sales	SG&A as a percentage of net sales	42.4		%	37.9		%	450 bps				SG&A as a percentage of net sales	42.5		%	38.8		%	370 bps
R&D as a percentage of net sales	R&D as a percentage of net sales	4.3		%	3.7		%	60 bps				R&D as a percentage of net sales	4.7		%	4.6		%	10 bps

Percentages are based on actual values and may not ~~recalculate~~reconcile due to rounding.

NM - Not meaningful

SG&A Expenses

SG&A ~~expenses~~expenses increased ~~primarily~~in part due toto professional service costs related to the ~~recently concluded investigation~~restructuring and ~~related remediation activities, including various legal, accounting and other professional service fees, as well as turnover and other employee-related costs. The increase due to these~~transformation initiatives. Headcount costs ~~was offset by lower headcount costs~~increased overall ~~which are in part~~ driven by ~~decreases~~incremental investments in the Company's sales personnel, increases in incentive ~~compensation.~~compensation expense relative to the prior year, and an increase in travel and trade event expenses as more customer-related interactions have returned to in-person format following the recovery from COVID-19. These increases were partially offset by a benefit from foreign exchange on operating expenses.

R&D Expenses

~~The increase in~~ R&D expenses ~~was primarily due~~were flat compared to ~~higher~~the first quarter of 2022. The Company continues to prioritize spend ~~within the T&E segment driven by increases in both headcount expenses and professional service fees~~ for ongoing investments in digital workflow solutions, product development initiatives, software development including clinical application suite and cloud deployment. R&D expense as a percentage of net sales decreased primarily due to higher sales in 2023 as compared to the prior year. The Company expects to continue to maintain ~~an expanded~~a level of investment in R&D that is at least 4% of annual net sales.

~~Goodwill Impairment~~

For the three months ended September 30, 2022, the Company recorded a goodwill impairment charge of $1,187 million. The charge was related to two reporting units within the Technologies & Equipment segment. For further information see Note 14, GoodwillRestructuring and ~~Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.~~

~~Intangible asset impairment and other costs~~Other Costs

During the three months ended ~~September 30, 2022,~~March 31, 2023, the Company recorded net expense of ~~$97~~$59 million of ~~intangible asset impairment~~restructuring and other costs which consist primarily of ~~an impairment charge of $94 million related to certain tradenames and trademarks within~~severance charges in conjunction with the ~~Technologies & Equipment segment and Consumables segment.~~restructuring plan announced in February 2023. For further details ~~see,~~refer to Note ~~9, Intangible asset impairment~~8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Segment Adjusted Operating Income


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)(a)	(in millions, except percentages)(a)	2022		2021		$ Change		% Change		(in millions, except percentages)(a)	2023		2022		$ Change		% Change

Technologies & Equipment	Technologies & Equipment	$	73	$	134	$	(61)	(45.5	%)	Technologies & Equipment	$	67	$	86	$	(19)	(22.1	%)

Consumables	Consumables	121		123		(2)		(1.6	%)	Consumables	131		135		(4)		(3.0	%)

(a) See Note 7,6, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

The decrease in adjusted operating income for both Technologies & Equipment and Consumables was primarily driven by ~~the decrease~~higher SG&A expenses as discussed above in ~~sales volumes~~this section and the higher costs for raw materials, labor, and distribution costs in the current year as a result of supply chain constraints and global inflation, offset by benefits from pricing ~~adjustments.~~adjustments and other margin improvements noted above.

4740

Other Income and Expense

Three Months Ended September 30,
(in millions) 2022 2021 $ Change % Change
Interest expense, net $ 14 $ 14 $ — NM
Other expense (income), net 9 5 4 NM
Net interest and other expense (income) $ 23 $ 19 $ 4

~~Percentages are based on actual values and may not recalculate due to rounding.~~


	Three Months Ended March 31,
(in millions)	2023		2022		$ Change		% Change

Interest expense, net	$	19	$	12	$	7	NM
Other expense (income), net	7		(2)		9		NM
Net interest and other expense (income)	$	26	$	10	$	16

NM - Not meaningful

Interest expense, net

Interest expense, net for the three months ended ~~September 30, 2022 was flat~~March 31, 2023 increased compared to the three months ended ~~September 30, 2021.~~March 31, 2022, driven primarily by higher interest rates on short-term and other borrowings.

Other expense (income), net

Other expense (income), net for the three months ended ~~September 30, 2022~~March 31, 2023 compared to the three months ended ~~September 30, 2021 was~~March 31, 2022 is as follows:


		Three Months Ended September 30,						Three Months Ended March 31,
(in millions)	(in millions)	2022		2021		$ Change			(in millions)	2023		2022		$ Change

Foreign exchange (gain) loss (a)		$	3	$	8	$	(5)
Loss (income) from equity method investments		4		(1)		5
Foreign exchange loss (gain) (a)									Foreign exchange loss (gain) (a)	$	4	$	(4)	$	8

Defined benefit pension plan expenses	Defined benefit pension plan expenses	2		2		—			Defined benefit pension plan expenses	2		2		—
Other non-operating loss (gain)		—		(4)		4
Other non-operating loss									Other non-operating loss	1		—		1
Other expense (income), net	Other expense (income), net	$	9	$	5	$	4		Other expense (income), net	$	7	$	(2)	$	9

(a) Foreign exchange losses (gains) are primarily related to the revaluation of intercompany payables and loans.

In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, effective April 1, 2022, the functional currency of the Company's Turkish subsidiaries was changed to the U.S. dollar, the reporting currency of the parent. The impact of recognizing foreign currency gains and losses resulting from this change in functional currency were not material to the period.

Income Taxes and Net Income


		Three Months Ended September 30,									Three Months Ended March 31,
(in millions, except percentages)	(in millions, except percentages)	2022			2021			$ Change		(in millions, except percentages)	2023			2022			$ Change

(Benefit) provision for income taxes	(Benefit) provision for income taxes	$	(164)		$	29		$	(193)	(Benefit) provision for income taxes	$	(5)		$	18		$	(23)

Effective income tax rate	Effective income tax rate	13.2		%	25.8		%			Effective income tax rate	18.4		%	20.8		%

Net (loss) income attributable to Dentsply Sirona	Net (loss) income attributable to Dentsply Sirona	$	(1,077)		$	84		$	(1,161)	Net (loss) income attributable to Dentsply Sirona	$	(19)		$	69		$	(88)

Net (loss) income per common share - diluted	Net (loss) income per common share - diluted	$	(5.01)		$	0.38				Net (loss) income per common share - diluted	$	(0.09)		$	0.32

Percentages are based on actual values and may not ~~recalculate due to rounding.~~

~~Provision for income taxes~~

For the three months ended September 30, 2022, the income tax benefit is $164 million as compared to the tax expense of $29 million during the three months ended September 30, 2021. This tax benefit as compared to the tax expense in prior period is driven primarily by the impairment of certain identified goodwill and indefinite-lived intangibles. The tax benefit attributed to the impact of the impairments is $183 million and is not considered discrete to the period. Refer to Note 14, Goodwill and Intangible Assets in Item 1 of this Form 10-Q for further discussion of the impairments.

During the three months ended September 30, 2022, changes in tax expense for other discrete tax matters was $6 million and is primarily composed of changes arising from income tax filings in certain jurisdictions, offset by uncertain tax positions and related interest expense.

During the three months ended September 30, 2021, the Company recorded $4 million of tax expense for other discrete tax matters primarily related to changes in uncertain tax positions and related interest expense, and tax rate changes impacting the carrying value of deferred taxes, offset by share-based compensation activity and changes in valuation allowances.

The Company continues to reassess the realizability of its deferred tax assets and, after weighing all positive and negative evidence, continues to maintain a valuation allowance on certain deferred tax assets.

~~RESULTS OF OPERATIONS, NINE MONTHS ENDED SEPTEMBER 30, 2022 COMPARED TO NINE MONTHS ENDED SEPTEMBER 30, 2021~~

~~Net Sales~~

~~The Company's net sales for the nine months ended September 30, 2022 and 2021, and the reconciliation to organic sales are as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 2,939 $ 3,128 $ (189) (6.0 %)
Foreign exchange impact (6.3 %)
Acquisitions 0.1 %
Divestitures and discontinued products (0.1 %)
Organic sales 0.3 %

~~Percentages are based on actual values and may not recalculate due to rounding.~~

~~The increase in organic sales was~~ ~~due to~~ ~~benefits from price increases and strong performance in the T&E segment in markets outside the United States as explained below. These increases were largely offset by~~ ~~overall weaker performance in the United States as explained below, including sales of CAD/CAM and Endodontic & Restorative Consumables products, and the ongoing~~ impact of global supply chain constraints and reduction in volumes due to product availability, particularly for certain Equipment & Instruments products which rely on electronic components. Results were also negatively impacted by COVID-19 variants on reduced demand from patient traffic in certain markets, particularly China.

~~Net Sales by Segment~~

~~Technologies & Equipment~~

~~Net sales for the nine months ended September 30, 2022 and 2021, and reconciliation of net sales to organic sales is as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 1,716 $ 1,824 $ (108) (5.9 %)
Foreign exchange impact (7.4 %)
Acquisitions 0.2 %
Organic sales 1.3 %

~~Percentages are based on actual values and may not recalculate due to rounding.~~

The increase in organic sales was primarily due to strong performance for Implants and Equipment & Instruments, partly as a result of the benefit of price increases. These positive drivers were offset by the impact of ongoing global supply chain constraints ~~and reduction in volumes due to product availability, particularly for certain Equipment & Instruments products which rely on electronic components~~, as well as the impact of COVID-19 reducing sales volumes in certain markets, particularly China. Sales of CAD/CAM products in the United States were also negatively impacted by high dealer inventory levels at the start of the year, as explained below.

~~Consumables~~

~~Net sales for the nine months ended September 30, 2022 and 2021, and reconciliation of net sales to organic sales is as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 1,223 $ 1,304 $ (81) (6.2 %)
Foreign exchange impact (4.8 %)
Divestitures and discontinued products (0.2 %)
Organic sales (1.2 %)

~~Percentages are based on actual values and may not recalculate due to rounding.~~

The decrease in organic sales was due to the weaker sales for Endodontic & Restorative products, particularly in the United States. Sales were also negatively impacted by ongoing global supply chain constraints affecting the ability to fulfill orders, and the impact of COVID-19 variants on sales volumes in certain markets, particularly China. Sales during the nine months of 2021 benefited from a restocking of products by customers as part of the overall recovery from the pandemic. The decline in sales volume was partly offset by strong performance for Preventive Consumables an~~d the benefit from the price increases.~~

~~Net Sales by Region~~

~~United States~~

~~Net sales for the nine months ended September 30, 2022 and 2021, and reconciliation of net sales to organic sales is as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 1,023 $ 1,094 $ (71) (6.5 %)
Foreign exchange impact (1.1 %)
Acquisitions 0.2 %
Divestitures and discontinued products (0.1 %)
Organic sales (5.5 %)

~~Percentages are based on actual values and may not recalculate due to rounding.~~

~~The decrease in organic sales was attributable to both segments, driven primarily by lower wholesale volumes for Restorative~~ and CAD/CAM products, due in part to high dealer inventory at the start of the year. Dealer inventory on hand for CAD/CAM units was approximately $50 million higher at the start of 2022 than at the beginning of 2021. The level of inventory was reduced by approximately $30 million during the first nine months of 2022, compared to a build in inventory levels of approximately $80 million in the first nine months of 2021, partly as a result of incremental incentives offered during that period which did not recur in 2022. Sales vol~~umes during the nine months ended September 30, 2022, were also negatively impacted by ongoing global supply chain constraints affecting the ability to fulfill orders for certain Equipment & Instruments, C~~AD/CAM and Consumables products, and the impact of COVID-19 on demand early in the first quarter. The decline in sales volume was partly offset by sales growth in the Equipment & Instruments business and a benefit from price increases.

~~Europe~~

~~Net sales for the nine months ended September 30, 2022 and 2021, and reconciliation of net sales to organic sales is as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 1,183 $ 1,239 $ (56) (4.5 %)
Foreign exchange impact (9.5 %)
Organic sales 5.0 %

~~Percentages are based on actual values and may not recalculate due to rounding.~~

The increase in organic sales was primarily due to overall higher volumes for Equipment & Instruments, CAD/CAM, Implants and Endodontic & Restorative Consumables products as a result of favorable market trends and demand, as well as a benefit from price increases. ~~The organic sales growth was partly suppressed by ongoing global supply chain constraints, particularly for certain Equipment & Instruments products which rely on electronic components.~~

~~Rest of World~~

~~Net sales for the nine months ended September 30, 2022 and 2021, and reconciliation of net sales to organic sales is as follows:~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Net sales $ 733 $ 795 $ (62) (7.7 %)
Foreign exchange impact (8.5 %)
Acquisitions 0.1 %
Divestitures and discontinued products (0.2 %)
Organic sales 0.9 %

~~Percentages are based on actual values and may not recalculate due to rounding.~~

The increase in organic sales was primarily due to higher sales for CAD/CAM products. This increase was partly offset by supply shortages for certain Equipment & Instruments products, and the adverse impact of COVID-19 on volumes, particularly in China which was affected by lower demand resulting from ongoing government restrictions affecting patient traffic. In the third quarter of 2022, the Company began to see softer demand for Implants products in China ahead of the local volume based procurement program taking effect. Although sales have not yet been materially impacted, the Company expects sales of our Implants products in China will be negatively affected by price reductions as a result of this program which is anticipated to take effect beginning late in the fourth quarter of 2022 or the first quarter of 2023.

~~Gross Profit~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Gross profit $ 1,610 $ 1,743 $ (133) (7.7 %)
Gross profit as a percentage of net sales 54.8 % 55.7 % (90) bps

~~Percentages are based on actual values and may not recalculate due to rounding.~~

~~Gross profit was negatively impacted by foreign currency translation headwinds of~~ ~~$119 million~~ and a decrease in sales volumes during the period. Gross profit margins as a percentage of net sales declined in the current period due to the impact of higher raw materials, labor, and distribution costs as a result of supply chain constraints and global inflation during the period, partly offset by the benefit of sales price increases.

~~Operating Expenses~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Selling, general, and administrative expenses ("SG&A") $ 1,187 $ 1,174 $ 13 1.1 %
Research and development expenses ("R&D") 131 122 9 7.7 %
Goodwill impairment 1,187 — 1,187 NM
Intangible asset impairment and other costs 107 11 96 NM
SG&A as a percentage of net sales 40.4 % 37.5 % 290 bps
R&D as a percentage of net sales 4.5 % 3.9 % 60 bps

~~Percentages are based on actual values and may not recalculate due to rounding.~~

~~SG&A Expenses~~

~~SG&A expenses increased primarily due t~~o costs related to the recently concluded investigation and related remediation activities, including various legal, accounting and other professional service fees, as well as turnover and other employee-related costs. The increase due to these costs was o~~ffset by lower headcount costs overall which are in part driven by decreases in incentive compensation.~~

~~R&D Expenses~~

The increase in R&D expenses was primarily due to an increase in spend within the T&E segment driven by increases in both headcount expenses and professional service fees for ongoing investments in digital workflow solutions, product development initiatives, software development including clinical application suite and cloud deployment. The Company expects to maintain an expanded level of investment in R&D that is at least 4% of annual net sales.

~~Goodwill Impairment~~

For the nine months ended September 30, 2022, the Company recorded a goodwill impairment charge of $1,187 million. The charge was related to two reporting units within the Technologies & Equipment segment. For further information see Note 14, Goodwill and Intangible Assets, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

~~Intangible asset impairment and other costs~~

During the nine months ended September 30, 2022, the Company recorded net expense of $107 million of intangible asset impairment and other costs which consist primarily of an impairment charge of $94 million related to certain tradenames and trademarks within the Technologies & Equipment segment and Consumables segment and $13 million in connection with the various restructuring initiatives. For further details see, Note 9, Intangible asset impairment and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

~~Segment Adjusted Operating Income~~

Nine Months Ended September 30,
(in millions, except percentages)(a)
2022 2021 $ Change % Change
Technologies & Equipment $ 278 $ 391 $ (113) (28.9 %)
Consumables 398 426 (28) (6.6 %)

(a) See Note 7, Segment Information, in the Notes to Unaudited Consolidated Financial Statements in Item 1 of this Form 10-Q for a reconciliation from segment adjusted operating income to consolidated US GAAP income.

The decrease in adjusted operating income for both Technologies & Equipment and Consumables was primarily driven by the decrease in sales volumes and the higher costs for raw materials, labor, and distribution costs in the current year as a result of supply chain constraints and global inflation, offset by benefits from pricing adjustments.

~~Other Income and Expense~~

Nine Months Ended September 30,
(in millions, except percentages) 2022 2021 $ Change % Change
Interest expense, net $ 41 $ 43 $ (2) (2.6 %)
Other expense (income), net 20 4 16 NM
Net interest and other expense $ 61 $ 47 $ 14

~~Percentages are based on actual values and may not recalculate due to rounding.~~

~~NM - Not meaningful~~

~~Interest expense, net~~

Interest expense, net for the nine months ended September 30, 2022 decreased by $2 million compared to the nine months ended September 30, 2021, driven primarily by lower average long-term debt levels in 2022 relative to prior year.

~~Other expense (income), net~~

~~Other expense (income), net for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was as follows:~~

Nine Months Ended September 30,
(in millions) 2022 2021 $ Change
Gain on sales of non-core businesses $ — $ (7) $ 7
Foreign exchange (losses) gains (a)
(1) 7 (8)
Loss from equity method investments 14 1 13
Defined benefit pension plan expenses 6 8 (2)
Other non-operating loss (gain) 1 (5) 6
Other expense (income), net $ 20 $ 4 $ 16

~~(a) Foreign exchange gains (losses) are primarily related to the revaluation of intercompany payables and loans.~~

~~Income Taxes and Net Income~~

Nine Months Ended September 30,
(in millions, except per share amounts and percentages) 2022 2021 $ Change
(Benefit) provision for income taxes $ (128) $ 97 $ (225)
Effective income tax rate 12.1 % 24.9 %
Net (loss) income attributable to Dentsply Sirona $ (935) $ 292 $ (1,227)
Net (loss) income per common share - diluted $ (4.34) $ 1.32

~~Percentages are based on actual values and may not recalculate~~reconcile due to rounding.

Provision for income taxes

~~For~~The effective tax rate for the ~~nine~~three months ended ~~September 30,~~March 31, 2023, and 2022 was 18.4% and 20.8%, respectively. The decrease in the ~~income~~effective tax ~~benefit was $128 million as compared~~rate is primarily related to the ~~tax expense~~geographic mix of $97 million during the nine months ended September 30, 2021. This tax benefit as compared to the tax expense in prior period was driven primarily by the impairment of certain identified goodwill and indefinite-lived intangibles. The tax benefit attributed to the impact of the impairments is $183 million and is not considered discrete to the period. Refer to Note 14, Goodwill and Intangible Assets in Item 1 of this Form 10-Q for further discussion of the impairments.

During the nine months ended September 30, 2022, tax expense for other discrete tax matters was $7 million, which was primarily composed of changes arising from income tax filings in certain jurisdictions, offset by uncertain tax positions and related interest expense.revenue.

5441

During the nine months ended September 30, 2021, the Company recorded $11 million of tax expense for discrete tax matters of which $7 million was primarily related to changes in uncertain tax positions and related interest expense and tax rate changes impacting the carrying value of deferred taxes, offset by shared based compensation activity and changes in valuation allowances. The Company also recorded $4 million of tax expense as a discrete item related to business divestitures.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

There have been no changes to the critical accounting policies as disclosed in the ~~2021~~2022 Form 10-K/A filed on November 7, 2022 other than those changes explained in Part I, Item 1, Note 1, Significant Accounting Policies, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q.10-K.

Goodwill Impairment

Goodwill represents the excess cost over the fair value of the identifiable net assets of businesses acquired. Goodwill is not amortized; instead, it is tested for impairment annually or more frequently if events or circumstances indicate that the carrying value of goodwill may be ~~impaired.~~impaired, or if a decision is made to sell a business. Judgment is involved in determining if an indicator of impairment has occurred during the course of the year. Such indicators may include a decline in expected cash flows, unanticipated competition or slower growth rates, among others. When testing goodwill for impairment, the Company may assess qualitative factors for its reporting units to determine whether it is "more likely than not" that the fair value of a reporting unit is less than its carrying amount including goodwill. Alternatively, the Company may bypass this qualitative assessment and perform the quantitative goodwill impairment test. It is important to note that fair values which could be realized in an actual transaction may differ from those used to evaluate the impairment of goodwill.

Goodwill is allocated among reporting units and evaluated for impairment at that level. The Company's reporting units are either an operating segment or one level below its operating segments, as determined in accordance with ASC 350.

In conjunction with the preparation of the financial statements for the three months ended September 30, 2022, the Company identified "more likely than not" indicators of impairment for two of its reporting units, and as a result, the Company recorded pre-tax goodwill impairment charges related to its Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment of $1,100 million and $87 million, respectively. The goodwill impairment charge was primarily driven by macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows. At September 30, 2022, the remaining goodwill related to the Digital Dental Group and Equipment & Instruments reporting units was $234 million and $192 million, respectively. As the fair value of these reporting units approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. For further information, see Part 1, Item 1, Note 14, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q.

To determine the fair value of the reporting units, the Company used a discounted cash flow model which utilizes both internal and market-based data as its valuation technique. The discounted cash flow model uses five-to-ten year forecasted cash flows plus a terminal value based on capitalizing the last period's cash flows using a perpetual growth rate. The Company's significant assumptions in the discounted cash flow model include, but are not limited to, the weighted average cost of capital, revenue growth rates (including perpetual growth rates), and operating margin percentages of the reporting unit's business. These assumptions were developed in consideration of current market conditions. The Company reconciled the aggregate fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions.

Indefinite-Lived Intangible Asset Impairment

Indefinite-lived intangible assets consist of tradenames, trademarks and ~~trademarks~~in process R&D and are not subject to amortization; instead, they are tested for impairment annually or more frequently if events or circumstances indicate that the carrying value of indefinite-lived intangible assets may be impaired or if a decision is made to sell a business.

In preparing the financial statements for the quarter ended September 30, 2022, in conjunction with the goodwill impairment, the Company tested the intangible assets related to the businesses within the Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment for impairment. The Company also identified an indicator of impairment for indefinite-lived intangible assets within the Consumables reporting unit within the Consumables segment. Intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method, or using a qualitative assessment. The Company's significant assumptions in the relief from royalty method included, but were not limited to, revenue growth rates (including perpetual growth rates), royalty rates, and discount rates. As a result, the Company recorded an impairment charge of $66 million, $26 million and $2 million for the Digital Dental Group, Equipment & Instruments and Consumables reporting units, respectively, for its indefinite-lived intangible assets for the three months ended September 30, 2022. The impairment charge was primarily driven by macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows. This charge was recorded in Intangible asset impairment and other costs in the Consolidated Statements of Operations. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. For further information, see Part 1, Item 1, Note 14, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q.

For the Company’s indefinite-lived intangible assets that were not impaired, the Company applied a hypothetical sensitivity analysis. If the fair value of each of these indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 100 basis points as of September 30, 2022, the fair value of certain indefinite-lived intangible assets within the Technologies & Equipment and Consumables segments would be less than book value and are considered at-risk based on the sensitivity analysis. The carrying value of these indefinite-lived intangibles within the Technologies & Equipment and Consumables segments was $43 million and $30 million, respectively, at September 30, 2022. Any further deteroriation in key assumptions could result in impairment charges in the future.

The fair value of acquired tradenames and trademarks is estimated by the use of a relief from royalty method, which values an indefinite-lived intangible asset by estimating the royalties saved through the ownership of an asset. Under this method, an owner of an indefinite-lived intangible asset determines the arm’s length royalty that likely would have been charged if the owner had to license the asset from a third party. The royalty rate, which is based on the estimated rate applied against forecasted sales, is tax-effected and discounted at present value using a discount rate commensurate with the relative risk of achieving the cash flow attributable to the asset. Management judgment is necessary to determine key assumptions, including revenue growth rates, perpetual revenue growth rates, royalty rates, and discount rates. Other assumptions are consistent with those applied to goodwill impairment testing.

The determination of fair value involves uncertainties around the forecasted cash flows as it requires management to make assumptions and apply judgment to estimate future business expectations. Those future expectations include, but are not limited to, macroeconomic factors such as higher cost of capital, cost inflation, unfavorable foreign currency impacts, and increased supply chain costs and new product development changes for these reporting units.

Goodwill and Indefinite-Lived Intangible Asset Impairment Results

No goodwill or indefinite-lived intangible impairment was identified as of April 1, 2022 in conjunction with the annual test.

In the third quarter of 2022, the Company experienced adverse macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain, and service costs, which contributed to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows. As a result, the Company identified indicators of a "more likely than not" impairment related to its Digital Dental Group and Equipment & Instruments reporting units and indefinite-lived intangible assets, included within the Technologies & Equipment segment, and indicators of a "more likely than not" impairment related to its indefinite-lived intangible assets for the Consumables reporting unit within the Consumables segment. As such, an interim impairment test was performed. The Company recorded a pre-tax goodwill impairment charge related to its Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment of $1,100 million and $87 million, respectively, and an indefinite-lived intangible asset impairment charge of $66 million and $26 million for the Digital Dental Group and Equipment & Instruments reporting units, respectively, within the Technologies & Equipment segment and a $2 million impairment charge for the Consumables reporting unit within the Consumables segment for the three months ended September 30, 2022.

In the fourth quarter of 2022, reductions in near-term forecasts for specific tradenames and continued adverse macroeconomic factors, including the impact of foreign exchange rates, resulted in indicators of a "more likely than not" impairment for certain indefinite-lived intangible assets within the Equipment & Instruments reporting unit within the Technologies & Equipment segment and the Consumables reporting unit within the Consumables segment. As such, an impairment test was performed during the fourth quarter resulting in an intangible asset impairment charge of $2 million and $4 million for indefinite-lived intangible assets within the Equipment & Instruments and Consumables reporting units, respectively, for the three months ended December 31, 2022.

Refer to Part I, Item 1, Note ~~14,~~13, Goodwill and Intangible Assets, in the Notes to the Unaudited Consolidated Financial Statements of this Form 10-Q for further discussion of the Company's annual goodwill and indefinite-lived intangible asset impairment testing.

LIQUIDITY AND CAPITAL RESOURCES


		Nine Months Ended September 30,							Three Months Ended March 31,
(in millions)	(in millions)	2022		2021		$ Change		(in millions)	2023		2022		$ Change

Cash provided by (used in):
Cash (used in) provided by:								Cash (used in) provided by:
Operating activities	Operating activities	$	375	$	435	$	(60)	Operating activities	$	(21)	$	93	$	(114)
Investing activities	Investing activities	(109)		(319)		210		Investing activities	(37)		(43)		6
Financing activities	Financing activities	(168)		(257)		89		Financing activities	17		(10)		27
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(19)		(16)		(3)		Effect of exchange rate changes on cash and cash equivalents	(6)		(5)		(1)
Net increase (decrease) in cash and cash equivalents		$	79	$	(157)	$	236
Net (decrease) increase in cash and cash equivalents								Net (decrease) increase in cash and cash equivalents	$	(47)	$	35	$	(82)

Cash ~~provided by~~used in operating activities decreased primarily as a result of changes in working capital including lower liabilities for trade accounts payables, higher operating expenses, and lower collections from sales during the current period, resulting in an operating cash outflow for the first quarter of 2023. At March 31, 2023, the number of days for sales outstanding in accounts receivable increased by 3 days to 58 days as ~~well as a build-up~~compared to 55 days at December 31, 2022, and the number of days of sales in inventory ~~partly~~increased by 2 days to 139 days at March 31, 2023 as ~~a consequence of temporary COVID-19 related shutdowns in China.~~compared to 137 days at December 31, 2022. These decreases in operating cash were offset by other changes in working capital including ~~higher liabilities for trade accounts payables and a decrease~~an increase in accounts receivable. At September 30, 2022, the number of days for sales outstanding in accounts receivable increased by 1 day to 61 days as compared to 60 days at December 31, 2021, and the number of days of sales in inventory increased by 27 days to 137 days at September 30, 2022 as compared to 110 days at December 31, 2021.accrued liabilities.

The slight decrease in cash used in investing activities was primarily due to lower ~~cash paid for acquisitions of $248 million, partially offset by higher~~ capital expenditures of ~~$16 million, and less cash received on sale of non-strategic businesses of $27~~$5 million. The Company estimates capital expenditures to be in the range of approximately $150 million to ~~$160~~$170 million for the full year ~~2022~~2023 and expects these investments to include expansion of facilities to provide incremental space for growth and to consolidate operations for enhanced efficiencies.

The ~~decrease in~~increase of cash ~~used in~~provided by financing activities compared to the first quarter of prior year was primarily driven by ~~lower payments on long-term borrowings of $295 million,~~ ~~offset by lower~~higher proceeds from short-term borrowings of ~~$83~~$35 million. The Company's total borrowings increased by a net $214 million ~~primarily from~~ during the three months ended March 31, 2023, mainly due to the use of the Company's commercial paper program ~~higher cash outflows related to stock repurchases~~and an increase of ~~$60~~$11 million ~~and reduced proceeds from exercises of stock options of $41 million. As a result of this activity, combined with the impact~~ due to exchange rate fluctuations on debt denominated in foreign ~~currencies, the Company's total borrowings decreased by a net $112 million during the nine months ended September 30, 2022.~~currencies.

During the ~~nine~~three months ended ~~September 30, 2022,~~March 31, 2023, the Company entered into an accelerated share repurchase agreement ("ASR Agreement") of $150 million with approximately ~~2.4~~3.1 million shares delivered during March ~~2022~~2023 at a volume-weighted average price of ~~$50.44.~~$38.74 representing $120 million of the total anticipated repurchase. In April ~~2022~~2023, an additional ~~0.7~~0.8 million shares were delivered upon the final settlement of the ASR Agreement resulting in a total ~~3.1~~3.9 million shares repurchased under the agreement. At ~~September 30, 2022, $740~~March 31, 2023, prior to the additional share delivery of $30 million in April, $620 million of authorization remained available for future share repurchases. Additional share repurchases, if any, may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions, or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. At ~~September 30, 2022,~~March 31, 2023, the Company held ~~49.6~~52.0 million shares of treasury stock.

The Company's ratio of total net debt to total capitalization was as follows:

(in millions, except percentages) September 30, 2022 December 31, 2021
Current portion of debt $ 246 $ 182
Long-term debt 1,737 1,913
Less: Cash and cash equivalents 418 339
Net debt $ 1,565 $ 1,756
Total equity 3,614 4,997
Total capitalization $ 5,179 $ 6,753
Total net debt to total capitalization ratio 30.2 % 26.0 %


(in millions, except percentages)	March 31, 2023			December 31, 2022

Current portion of debt	$	316		$	118
Long-term debt	1,842			1,826
Less: Cash and cash equivalents	318			365
Net debt	$	1,840		$	1,579

Total equity	3,638			3,812
Total capitalization	$	5,478		$	5,391

Total net debt to total capitalization ratio	33.6		%	29.3		%

At ~~September 30, 2022,~~March 31, 2023, the Company had a total remaining borrowing capacity of ~~$503~~$433 million under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company's borrowing capacity includes a $700 million credit facility from 2018 available through July 28, 2024. The Company also has available an aggregate $500 million under a U.S. dollar commercial paper facility. The $700 million revolver serves as a back-up to the commercial paper facility, thus the total available credit under the commercial paper facility and the multi-currency revolving credit facility in the aggregate is $700 million. The Company had ~~$224~~$294 million outstanding borrowings under the commercial paper facility at ~~September 30, 2022~~March 31, 2023 resulting in ~~$476~~$406 million remaining available under the revolving credit and commercial paper facilities. The Company also has access to $48 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings. The lines of credit have no major restrictions and are provided under demand notes between the Company and the lending institutions. At ~~September 30, 2022,~~March 31, 2023, the Company ~~has~~had $21 million outstanding under short-term borrowing arrangements.

The Company’s revolving credit facility, term loans and senior notes contain certain covenants relating to the Company's operations and financial condition. The most restrictive of these covenants are: a ratio of total debt outstanding to total capital not to exceed 0.6, and a ratio of operating income excluding depreciation and amortization to interest expense of not less than 3.0 times, in each case, as such terms are defined in the relevant agreement. Any breach of any such covenants would result in a default under the existing debt agreements that would permit the lenders to declare all borrowings under such debt agreements to be immediately due and payable and, through cross default provisions, would entitle the Company's other lenders to accelerate their loans. At ~~September 30, 2022,~~March 31, 2023, the Company was in compliance with these covenants.

~~Additionally, the Company is required under certain of its debt agreements to deliver or make available to borrowers its~~ unaudited financial statements on a timely basis each quarter along with the necessary certifications. As a result of the Company’s failure to file its unaudited financial statements for the fiscal quarters ended March 31, 2022 and June 30, 2022 by the reporting deadlines, the Company obtained the consents of the requisite lenders and noteholders of its outstanding indebtedness to extend the time period for delivery of such unaudited financial statements until November 14, 2022. Those financial statements were delivered on November 9, 2022 and therefore, the Company has not suffered an event of default as a result of the previously delayed filings.

The Company expects on an ongoing basis to be able to finance operating cash requirements, capital expenditures, and debt service from the current cash, cash equivalents, cash flows from operations and amounts available under its existing borrowing facilities. The Company's credit facilities are further discussed in Note ~~13,~~12, Financing Arrangements, to the Unaudited Consolidated Financial Statements of this Form 10-Q.

The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries' operating activities and future foreign investments. The Company has the ability to repatriate cash to the United States, which could result in an adjustment to the tax liability for foreign withholding taxes, foreign and/or U.S. state income taxes, and the impact of foreign currency movements. At ~~September 30, 2022~~March 31, 2023, management believed that sufficient liquidity was available in the United States and expects this to remain for the next twelve months. The Company has repatriated and expects to continue repatriating certain funds from its non-U.S. subsidiaries that are not needed to finance local operations, however, these particular repatriation activities have not and are not expected to result in a significant incremental tax liability to the Company.

The Company continues to review its debt portfolio and may refinance additional debt or add debt in the near-term based on strategic capital management. The Company believes there is sufficient liquidity available for the next twelve months.

Material Trends in Capital Resources

On February 14, 2023, the Board of Directors of the Company approved a plan to restructure the Company’s business to improve operational performance and drive shareholder value creation. The plan includes a restructuring of the business through a new operating model with five global business units, optimization of central functions and overall management infrastructure, and other efforts aimed at cost savings. The restructuring plan anticipates a reduction in the Company’s global workforce of approximately 8% to 10%, subject to co-determination processes with employee representative groups in countries where required. The plan is expected to be substantially completed by mid 2024 and result in $200 to $225 million in annual cost savings

As of March 31, 2023, in conjunction with this plan the Company has incurred $57 million in restructuring charges primarily related to employee transition, severance payments, employee benefits, and facility closure costs and $8 million in other non-recurring costs related to the restructuring activity which mostly consist of legal, consulting and other professional service fees. In our announcement of the plan in our Current Report on Form 8-K dated February 16, 2023, the Company previously estimated that in total we would incur up to $165 million in one-time charges. The Company now expects to incur between $115 to $135 million in one-time charges, comprising of $80 to $100 million in restructuring expenditures and charges, and $35 million in other non-recurring charges, the majority of which will be incurred as cash expenditures in 2023. The estimates of these charges and their timing are subject to several assumptions, including local law requirements in various jurisdictions and co-determination aspects in countries where required. Actual amounts may differ materially from estimates. In addition, the Company may incur other charges or cash expenditures in connection with this plan which are not currently contemplated. For further details refer to Note 8, Restructuring and other costs, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Beginning in the second quarter of 2022, the Company's financial results have also been impacted by the costs associated with the internal investigation conducted by the Audit and Finance Committee and assisted by independent legal counsel and forensic accountants. These costs have included professional service fees associated with the investigation itself, as well as third party accounting and legal costs incurred by management to make assessments and revisions and begin remediation activities in response to the investigation's findings. Additionally, the Company has incurred severance costs associated with its remedial personnel actions, as well as special one-time costs in connection with retention of key personnel. These costs totaled approximately ~~$45~~$61 million for the ~~nine~~year ended December 31, 2022, with an additional $7 million incurred for the three months ended ~~September 30, 2022.~~March 31, 2023. Although the investigation has been completed at the time of this filing, related costs are expected to continue ~~as a material trend into the fourth quarter of 2022 and beyond~~further into 2023 as the Company completes its remediation activities described in Part I, Item 4 Controls and Procedures of this Form 10-Q, and incurs legal defense costs pertaining to the matters described in Note 1514 Commitments and Contingencies to the financial statements included in Part I, Item 1.

NEW ACCOUNTING PRONOUNCEMENTS

Refer to Part 1, Item 1, Note 1, Significant Accounting Policies, to the Unaudited Consolidated Financial Statements of this Form 10-Q for a discussion of recent accounting pronouncements.

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes from the information provided in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our ~~Annual Report on~~2022 Form ~~10-K/A for the fiscal year ended December 31, 2021.~~10-K.

Item 4 – Controls and Procedures

Internal Investigation and Accounting Errors

As described in the Explanatory Note to the Form 10-K for the year ended December 31, 2021 as amended and filed on November 7, 2022 (the "2021 Form 10-K/A"), the Audit and Finance Committee, assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company, which was completed in the fourth quarter of 2022 (the "Investigation").

The findings of the Investigation are described in the Explanatory Note of the 2021 Form 10-K/A referenced above.

Distinct from the matters pertaining to the Investigation, and as a consequence of a separate but concurrent accounting review, management identified certain errors in the manner in which it recognized variable consideration related to certain incentive programs. During this review, it was also determined that the Company utilized incorrect accounting and assumptions in the determination of estimates related to its sales returns provisions, warranty reserve provisions, and variable consideration.

In connection with the Investigation and the subsequent accounting review in 2022, management reevaluated the effectiveness of the Company’s internal control over financial reporting and identified control deficiencies related to these matters, which the Company concluded represented material weaknesses in the Company’s internal control over financial reporting as of December 31, 2021 and which the Company has concluded remain unremediated as of March 31, 2023.

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

The ~~Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s~~Company has established disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as ~~of September 30, 2022,~~amended (the "Exchange Act") is recorded, processed, summarized and reported, within the ~~end of~~time periods specified in the ~~period covered by this report. Based on~~SEC’s rules and forms and that ~~evaluation,~~such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, ~~concluded that~~as appropriate to allow timely decisions regarding required disclosure.

The Company's management, with the ~~Company’s~~participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures ~~(as~~as defined in Rules 13a-15(e) and 15d-15(e) under the ~~Securities~~ Exchange Act ~~of 1934, as amended)~~ as of March 31, 2023, the end of the period covered by this report, ~~were~~and concluded the Company’s disclosure controls and procedures are not effective ~~as of September 30, 2022 because of~~due to the material weaknesses in internal control over financial reporting as described below under “Material Weaknesses in Internal Control over Financial Reporting."

Notwithstanding the ineffective disclosure controls and procedures as a result of the identified material weaknesses, the Chief Executive Officer and Chief Financial Officer have concluded that the consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, the Company’s financial position, results of operations and cash flows in accordance with US GAAP.

Material Weaknesses in Internal Control over Financial Reporting

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will not be prevented or detected on a timely basis.

Management identified the following material weaknesses in the Company's internal control over financial reporting as of ~~September 30, 2022:~~March 31, 2023:

a.The Company did not design and maintain an effective internal control environment, as former management failed to set an appropriate tone at the top. Specifically, certain members of senior management, including the Company’s former Chief Executive Officer and former Chief Financial Officer, engaged in conduct that was inconsistent with the Company’s culture of compliance and Code of Ethics and Business Conduct.

b.The Company did not maintain a sufficient complement of personnel with an appropriate level of knowledge about accounting for variable consideration related to customer incentive arrangements in a manner commensurate with our financial reporting requirements.

These material weaknesses contributed to the following additional material weakness:

c.The Company did not design and maintain effective controls associated with approving, communicating, and accounting for incentive arrangements with customers, impacting the completeness and accuracy of revenues, including variable consideration.

These material weaknesses resulted in the restatement of our consolidated financial statements for the year ended December 31, 2021, and the unaudited interim financial information for the three and nine months ended September 30, 2021. These material weaknesses also resulted in adjustments to substantially all of our accounts and disclosures for the interim and annual periods related to 2019, 2020, and 2021. Additionally, eachEach of these material weaknesses could result in a misstatement of substantially all of our account balances or disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected.

Remediation Plan and Status

~~In response to~~While the ~~matters discussed in the Explanatory Note,~~material weaknesses previously disclosed have not yet been remediated as of March 31, 2023, management is devoting substantial resources to the ~~planning and~~ ongoing implementation of remediation efforts to address the material weaknesses described herein, as well as other identified areas of risk. These remediation efforts, summarized below, which either have already been implemented or are continuing to be implemented, are intended to address both the identified material weaknesses and to enhance the Company’s overall internal control over financial reporting and disclosure controls and procedures.

With oversight from the Audit and Finance Committee and input from the Board of Directors, management ~~has begun designing~~is continuing to enhance and ~~implementing~~implement changes in processes and controls to remediate the material weaknesses described in Management’s Report on Internal Control Over Financial Reporting and to ~~enhance~~improve our internal control over financial reporting as noted below. Management and the Board of Directors, including the Audit and Finance Committee, are working to remediate the material weaknesses identified herein. ~~While the Company expects to take other remedial actions, actions~~Actions taken to date include:

a.Appointment of a new Chief Executive Officer, a new Chief Financial Officer and a new Chief Accounting Officer;

b.Termination of certain members of senior management as well as non-executive employees for violations of the Code of Ethics and Business ~~Conduct.~~Conduct;

c.Reviewed and enhanced the Company's Code of Ethics and Business Conduct including to clarify responsibilities related to the Company's financial reporting and disclosures;

d.Implementation of general training programs on revenue recognition for commercial and finance personnel;

e.Established requirements and provided trainings for employees who have a role in negotiating, assessing, agreeing, and accounting for customer incentive arrangements with distributors;

f.Implemented commercial contracting policies and provided training on new processes to individuals responsible for execution, oversight and review of customer incentive arrangements with customers; and

g.Implemented written policies and procedures to provide governance and establish responsibility for oversight of incentive arrangements provided to customers in North America, including the appropriate delegation of authority for such approvals.

In addition to the remedial actions taken to date, the Company is taking, or plans to take, the following actions, among others, to remediate the material weaknesses identified herein:

a.~~Review and enhance the Company’s Code of Ethics and Business Conduct to clarify responsibilities related to the Company’s financial reporting and disclosures and provide~~Provide incremental training to Company personnel on the updated Code of Ethics and Business Conduct;

b.Implement written policies and procedures to provide governance and establish responsibility for oversight of incentive arrangements provided to customers in China, including the appropriate delegation of authority for such approvals;

c.Formalize written policies and procedures to provide governance and establish responsibility for guidelines, documentation and oversight of product returns from customers when a contractual right to return exists in a customer agreement;

d.~~Require and provide trainings for employees who have a role in negotiating, assessing, agreeing, and accounting for customer incentive arrangements with distributors;~~

e.~~Provide training on new processes to individuals responsible for execution, oversight and review of customer incentive arrangements with customers;~~

f.Enhance processes to ensure all applicable terms and conditions for incentive-based programs and customer agreements are timely communicated to individuals responsible for accounting and financial reporting;

g.e.Strengthen internal controls over the accounting for customer incentive arrangements, ~~including:~~including implementing: (i) ~~implementing~~ formal controls to continuously review and document the methodology and assumptions used in estimating variable based incentives and (ii) formal controls to ensure the accuracy of the estimated accrued liability analysis;

h.f.Evaluate finance and commercial operations talent and address identified gaps; and

i.g.~~Enhance~~Establish a recurring cadence for future training programs on revenue recognition for commercial and finance personnel.

In addition, the Company took the following remedial actions to improve disclosure controls and procedures:

a.Enhanced existing Disclosure Committee responsibilities through adoption of a ~~more~~ formal charter, which identifies members and sets forth the roles and responsibilities of the Disclosure Committee, among other requirements; and

b.Implemented additional and ~~enhance~~enhanced existing sub-certifications and internal management representation letters, including providing training on the purpose of the sub-certification and ~~execution of these processes.~~the process for evaluating the representations.

Management developed a detailed plan and timetable for the implementation of the foregoing remediation efforts and ~~will~~continues to oversee the effective ~~execution.~~execution of the plan. In addition, under the direction of the Audit and Finance Committee, management will continue to identify and implement actions to improve the effectiveness of its disclosure controls and procedures and internal control over financial reporting, including plans to enhance its resources and training with respect to financial reporting and disclosure responsibilities and make necessary changes to policies and procedures to improve the overall effectiveness of such controls.

Management believes the foregoing efforts will effectively remediate the material weaknesses described above. As the Company continues to evaluate and ~~work to~~ improve its internal control over financial reporting and disclosure controls and procedures, management may determine to take additional measures to improve controls or determine to modify the remediation plan described above. The Company is working to remediate the material weaknesses as efficiently and effectively as possible with the goal of remediating each of the material weaknesses described above as soon as possible. Procedures to implement this remediation plan have to date required significant amounts of time, allocation of internal resources and external costs, and remaining remediation efforts will continue to place significant demands on financial and operational resources until this plan is completed.

As of the filing of this Form 10-Q, the material weaknesses described above have not ~~yet~~ been remediated. The material weaknesses described above cannot be considered remediated until the applicable controls have operated for a sufficient period of time and management has concluded, through testing, that these controls are designed and operating effectively. Accordingly, management will continue to monitor and evaluate the effectiveness of our internal control over financial reporting in the activities affected by the material weaknesses described above.

~~The Company's management will continue to work towards remediation of these material weaknesses to improve its internal control over financial reporting.~~

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company’s internal control over financial reporting that occurred during the three months ended ~~September 30, 2022~~March 31, 2023 that have materially affected, or are reasonably likely to materially affect, its internal control over financial reporting.

6148

PART II – OTHER INFORMATION

Item 1 – Legal Proceedings

Refer to Part I, Item 1, Note 1514 Commitments and Contingencies, in the Notes to Unaudited Consolidated Financial Statements of this Form 10-Q.

Item 1A – Risk Factors

~~Except as noted below, there~~There have been no material changes to the risk factors as disclosed in Part 1A, “Risk Factors” in the ~~2021~~2022 Form ~~10-K/A.~~

The Company has recognized substantial goodwill impairment charges, most recently in Q3 2022, and may be required to recognize additional goodwill and indefinite-lived intangible asset impairment charges in the future.

The Company acquired other companies and intangible assets and may not realize all the economic benefit from those acquisitions, which could cause an impairment of goodwill or intangibles. The Company reviews amortizable intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. The Company tests goodwill and indefinite-lived intangibles for impairment at least annually. The valuation models used to determine the fair value of goodwill or indefinite-lived intangible assets are dependent upon various assumptions and reflect management's best estimates.

Following the recording of an aggregate of $3.5 billion in charges for impairment of certain businesses during 2017, 2018, and 2020, the Company had an aggregate amount of $3.9 billion in goodwill on its balance sheet as of June 30, 2022. In preparing the financial statements for the quarter ended September 30, 2022, the Company identified a triggering event and recorded a $1,187 million non-cash goodwill impairment charge associated with two reporting units within the Technologies & Equipment segment. At September 30, 2022, the remaining goodwill related to the Digital Dental Group and Equipment & Instruments reporting units was $234 million and $192 million, respectively. As the fair value of these reporting units approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. In addition, the Company tested the indefinite-lived intangible assets related to these businesses, along with certain indefinite-lived intangibles related to the Consumables segment, and determined that certain tradenames and trademarks were impaired, resulting in the recording of an impairment charge of $94 million for the three months ended September 30, 2022. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. ~~At September 30, 2022, the Company has $434 million in indefinite-lived intangible assets and $2.6 billion of goodwill recorded on its balance sheet.~~

The goodwill and indefinite-lived intangible asset impairment analyses are sensitive to changes in key assumptions used, such as discount rates, revenue growth rates, perpetual revenue growth rates, royalty rates, and operating margin percentages of the business as well as current market conditions affecting the dental and medical device industries in both the U.S. and globally. Given the uncertainty in the marketplace and other factors affecting management’s assumptions underlying the Company’s discounted cash flow model, the assumptions and projections used in the analyses may not be realized and the Company’s current estimates could vary significantly in the future, which may result in an additional goodwill or indefinite-lived intangible asset impairment charge at that time.10-K.

Item 2 – Unregistered Sales of Securities and Use of Proceeds

During the three months ended March 31, 2023, the Company had the following activity with respect to the share repurchase program:


(in millions, except per share amounts)	Total Number of Shares Purchased	Average Price Paid Per Share		Total Cost of Shares Purchased		Dollar Value of Shares that May be Purchased Under the Stock Repurchase Program
Period

January 1, 2023 to January 31, 2023	—	$	—	$	—	$	740
February 1, 2023 to February 28, 2023	—	—		—		740
March 1, 2023 to March 31, 2023	3.1	38.74		120		620
	3.1	$	38.74	$	120	$	620

On July 28, 2021 the Board of Directors approved a share repurchase program, up to $1.0 billion. ~~During the three months ended September 30, 2022,~~On March 3, 2023, the Company ~~had no repurchases of common shares under the stock repurchase program. At September 30, 2022, the Company had authorization~~entered into an ASR Agreement with a financial institution, to repurchase ~~$740~~$150 million of the Company's common stock. For further information on the ASR Agreement see Part I, Item 1, Note5, Earnings Per Common Share, in ~~shares~~the Notes to Unaudited Interim Consolidated Financial Statements of ~~common stock remaining under the share repurchase program.~~this Form 10-Q.

6249

~~Item 5 - Other Information~~

On September 2, 2022, the Company filed a current report on Form 8-K (the “Original 8-K”) regarding the separation of Walter Petersohn, the Company's Senior Vice President, Chief Commercial Officer, effective September 30, 2022. The Original 8-K stated that Mr. Petersohn and the Company mutually agreed upon Mr. Petersohn's separation. Following subsequent discussions with Mr. Petersohn, the Company now considers Mr. Petersohn's departure to be a termination without mutual agreement and Mr. Petersohn's effective date of termination has been revised to November 10, 2022.

Item 6 – Exhibits


Exhibit Number						Description
~~4.1~~						Consent Memorandum, dated August 11, 2022, by and among DENTSPLY SIRONA Inc., the Subsidiary Borrowers from time to time party thereto, the lender parties thereto and JPMorgan Chase Bank, N.A., as administrative agent.
~~4.2~~						Note Purchase Agreement Amendment and Consent, dated August 26, 2022, by and among DENTSPLY SIRONA Inc. and each of the holders of Notes parties thereto, with respect to that certain Note Purchase Agreement, dated December 11, 2015, by and among the Issuers and the holders of Notes set forth therein.
~~4.3~~						Note Purchase and Guarantee Agreement Amendment and Consent, dated August 26, 2022, by and among DENTSPLY SIRONA Inc., Sirona Dental Services GmbH and each of the holders of Notes parties thereto, with respect to that certain Note Purchase Agreement and Guarantee Agreement, dated October 27, 2016, by and among the Issuers and the holders of Notes set forth therein.
~~4.4~~						Note Purchase Agreement Amendment and Consent, dated August 26, 2022, by and among DENTSPLY SIRONA Inc. and each of the holders of Notes parties thereto, with respect to that certain Note Purchase Agreement, dated June 24, 2019, by and among the Issuers and the holders of Notes set forth therein.
~~4.5~~						Consent Memorandum, dated September 14, 2022, by and among DENTSPLY SIRONA Inc., the Subsidiary Borrowers from time to time party thereto, the lender parties thereto and JPMorgan Chase Bank, N.A., as administrative agent.
~~4.6~~						Consent Memorandum, dated November 4, 2022, by and among DENTSPLY SIRONA Inc., the Subsidiary Borrowers from time to time party thereto, the lender parties thereto and JPMorgan Chase Bank, N.A., as administrative agent.
~~4.7~~						Note Purchase Agreement Amendment No. 2 and Consent, dated November 5, 2022, by and among DENTSPLY SIRONA Inc and each of the holders of Notes parties thereto, with respect to that certain Note Purchase Agreement, dated December 11, 2015, by and among the Issuers and the holders of Notes set forth therein.
~~4.8~~						Note Purchase Agreement Amendment No. 2 and Consent, dated November 5, 2022, by and among DENTSPLY SIRONA Inc, Sirona Dental Services GmbH and each of the holders of Notes parties thereto, with respect to that certain Note Purchase and Guarantee Agreement, dated October 27, 2016, by and among the Issuers and the holders of Notes set forth therein.
~~4.9~~						Note Purchase Agreement Amendment No. 2 and Consent, dated November 5, 2022, by and among DENTSPLY SIRONA Inc and each of the holders of Notes parties thereto, with respect to that certain Note Purchase Agreement, dated June 24, 2019, by and among the Issuers and the holders of Notes set forth therein.
~~10.1~~						~~Dentsply Sirona Inc. Amended and Restated Key Employee Severance Benefits Plan, dated September 22, 2022.~~
~~10.2~~						~~Employment Agreement between DENTSPLY SIRONA Inc. and Simon D. Campion, entered into as of August 22, 2022.(1)~~
~~10.3~~						~~First Amendment to the Interim Chief Financial Officer Employment Agreement between DENTSPLY SIRONA Inc. and Barbara W. Bodem, dated as of September 22, 2022.(2)~~
~~10.4~~						~~Offer Letter between DENTSPLY SIRONA Inc. and Glenn Coleman, entered into as of September 22, 2022.(3)~~
31.1						Section 302 Certification Statement Chief Executive Officer
31.2						Section 302 Certification Statement Chief Financial Officer
32						Section 906 Certification Statements
101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						XBRL Taxonomy Extension Schema Document
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						XBRL Extension Labels Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

~~(1) Incorporated by reference to exhibit included in the Company's Form 8-K, dated August 25, 2022, File no. 0-16211.~~

~~(2) Incorporated by reference to exhibit included in the Company's Form 8-K, dated September 22, 2022, File no. 0-16211.~~

~~(3) Incorporated by reference to exhibit included in the Company's Form 8-K, dated September 22, 2022, File no. 0-16211.~~

6450

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.


/s/	Simon D. Campion	~~November 14, 2022~~May 3, 2023
	Simon D. Campion	Date
	President and
	Chief Executive Officer


/s/	Glenn G. Coleman	~~November 14, 2022~~May 3, 2023
	Glenn G. Coleman	Date
	Executive Vice President and
	Chief Financial Officer

6551



PART I	FINANCIAL INFORMATION	Page

Item 1	Financial Statements (unaudited)	54

	Consolidated Statements of Operations	54

	Consolidated Statements of Comprehensive Income (Loss)	65

	Consolidated Balance Sheets	76

	Consolidated Statements of Changes in Equity	87

	Consolidated Statements of Cash Flows	108

	Notes to Unaudited Interim Consolidated Financial Statements	119

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4235

Item 3	Quantitative and Qualitative Disclosures About Market Risk	5945

Item 4	Controls and Procedures	5945

PART II	OTHER INFORMATION

Item 1	Legal Proceedings	6249

Item 1A	Risk Factors	6249

Item 2	Unregistered Sales of Securities and Use of Proceeds	6249

Item 6	Exhibits	6450

Signatures		6551


			Weighted Average
			Useful Life
(in millions, except for useful life)	Amount		(in years)

Developed technology	$	66	15
In-process R&D	10		Indefinite
Total	$	76



	Nine Months Ended September 30, 2022
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	3	$	—
Interest rate swaps	—		Interest expense, net	(2)		—


Total for cash flow hedging	$	3		$	1	$	—

Hedges of Net Investments
Cross currency basis swaps	$	47	Interest expense, net	$	—	$	4

Foreign exchange forward contracts	24		Other expense (income), net	—		1

Total for net investment hedging	$	71		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	—
Foreign exchange forward contracts	(2)		Other expense (income), net	—		37

Total for fair value hedging	$	(2)		$	—	$	37



	Nine Months Ended September 30, 2021
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	(4)	$	1
Interest rate swaps	—		Interest expense, net	(4)		—


Total for cash flow hedging	$	3		$	(8)	$	1

Hedges of Net Investments
Cross currency basis swaps	$	6	Interest expense, net	$	—	$	5

Foreign exchange forward contracts	7		Other expense (income), net	—		—

Total for net investment hedging	$	13		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	1
Foreign exchange forward contracts	—		Other expense (income), net	—		18
Total for fair value hedging	$	—		$	—	$	19


	Nine Months Ended September 30,
(in millions, except per share amounts and percentages)	2022			2021			$ Change

(Benefit) provision for income taxes	$	(128)		$	97		$	(225)

Effective income tax rate	12.1		%	24.9		%





Net (loss) income attributable to Dentsply Sirona	$	(935)		$	292		$	(1,227)

Net (loss) income per common share - diluted	$	(4.34)		$	1.32